WO2002086100A2 - Expression of core-glycosylated hcv envelope proteins in yeast - Google Patents
Expression of core-glycosylated hcv envelope proteins in yeast Download PDFInfo
- Publication number
- WO2002086100A2 WO2002086100A2 PCT/BE2002/000063 BE0200063W WO02086100A2 WO 2002086100 A2 WO2002086100 A2 WO 2002086100A2 BE 0200063 W BE0200063 W BE 0200063W WO 02086100 A2 WO02086100 A2 WO 02086100A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hcv
- protein
- proteins
- virus
- glycosylated
- Prior art date
Links
- 101710091045 Envelope protein Proteins 0.000 title claims abstract description 126
- 101710188315 Protein X Proteins 0.000 title claims abstract description 126
- 230000014509 gene expression Effects 0.000 title claims abstract description 105
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 70
- 102100021696 Syncytin-1 Human genes 0.000 title claims abstract 25
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 188
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 167
- 238000000034 method Methods 0.000 claims abstract description 87
- 238000006206 glycosylation reaction Methods 0.000 claims abstract description 55
- 230000013595 glycosylation Effects 0.000 claims abstract description 54
- 241000235648 Pichia Species 0.000 claims abstract description 44
- 238000000746 purification Methods 0.000 claims abstract description 35
- 241000235070 Saccharomyces Species 0.000 claims abstract description 25
- 208000015181 infectious disease Diseases 0.000 claims abstract description 16
- 241000711549 Hepacivirus C Species 0.000 claims description 287
- 235000018102 proteins Nutrition 0.000 claims description 152
- 239000013598 vector Substances 0.000 claims description 98
- 210000004027 cell Anatomy 0.000 claims description 79
- 239000000203 mixture Substances 0.000 claims description 65
- 239000002245 particle Substances 0.000 claims description 49
- 241000320412 Ogataea angusta Species 0.000 claims description 47
- 239000000523 sample Substances 0.000 claims description 43
- 235000001014 amino acid Nutrition 0.000 claims description 42
- 229960005486 vaccine Drugs 0.000 claims description 34
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 32
- 101710125507 Integrase/recombinase Proteins 0.000 claims description 31
- 230000002441 reversible effect Effects 0.000 claims description 26
- SHFKGANKURXVMY-LCWPZEQJSA-N hcv e2 protein Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)CC1=CC=CC=C1 SHFKGANKURXVMY-LCWPZEQJSA-N 0.000 claims description 25
- 238000003018 immunoassay Methods 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 24
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 23
- 238000004113 cell culture Methods 0.000 claims description 23
- 229960002897 heparin Drugs 0.000 claims description 23
- 229920000669 heparin Polymers 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 235000018417 cysteine Nutrition 0.000 claims description 20
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 claims description 19
- 230000004048 modification Effects 0.000 claims description 19
- 238000012986 modification Methods 0.000 claims description 19
- 230000009466 transformation Effects 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 16
- 238000006277 sulfonation reaction Methods 0.000 claims description 15
- 108010058643 Fungal Proteins Proteins 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 12
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 11
- 239000012472 biological sample Substances 0.000 claims description 11
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 230000002255 enzymatic effect Effects 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 11
- 230000002427 irreversible effect Effects 0.000 claims description 11
- 101150082674 E2 gene Proteins 0.000 claims description 10
- 238000002955 isolation Methods 0.000 claims description 9
- 238000001042 affinity chromatography Methods 0.000 claims description 8
- 239000012990 dithiocarbamate Substances 0.000 claims description 8
- 230000002934 lysing effect Effects 0.000 claims description 8
- 210000005253 yeast cell Anatomy 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 claims description 7
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims description 6
- 230000002860 competitive effect Effects 0.000 claims description 6
- 238000009007 Diagnostic Kit Methods 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 3
- 230000003196 chaotropic effect Effects 0.000 claims description 2
- 238000007385 chemical modification Methods 0.000 claims 2
- 238000010668 complexation reaction Methods 0.000 claims 1
- 150000001945 cysteines Chemical class 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 19
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 6
- 238000012544 monitoring process Methods 0.000 abstract description 6
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 238000011321 prophylaxis Methods 0.000 abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 208000006454 hepatitis Diseases 0.000 abstract description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 abstract description 2
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 106
- 239000000047 product Substances 0.000 description 68
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 62
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 57
- 239000012634 fragment Substances 0.000 description 56
- 210000004962 mammalian cell Anatomy 0.000 description 55
- 239000013612 plasmid Substances 0.000 description 51
- 108020004414 DNA Proteins 0.000 description 50
- 102000053602 DNA Human genes 0.000 description 49
- 229940024606 amino acid Drugs 0.000 description 49
- 108090000765 processed proteins & peptides Proteins 0.000 description 42
- 150000001413 amino acids Chemical class 0.000 description 40
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 102000004196 processed proteins & peptides Human genes 0.000 description 35
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 33
- 239000000427 antigen Substances 0.000 description 32
- 108091007433 antigens Proteins 0.000 description 31
- 102000036639 antigens Human genes 0.000 description 31
- 238000001262 western blot Methods 0.000 description 31
- 108020004705 Codon Proteins 0.000 description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 30
- 230000027455 binding Effects 0.000 description 29
- 239000000872 buffer Substances 0.000 description 28
- 239000000463 material Substances 0.000 description 28
- 230000009257 reactivity Effects 0.000 description 28
- 238000010828 elution Methods 0.000 description 26
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 26
- 238000002965 ELISA Methods 0.000 description 25
- 238000011534 incubation Methods 0.000 description 25
- 238000010276 construction Methods 0.000 description 24
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 24
- 238000000855 fermentation Methods 0.000 description 24
- 230000004151 fermentation Effects 0.000 description 24
- 239000013605 shuttle vector Substances 0.000 description 24
- 238000001542 size-exclusion chromatography Methods 0.000 description 24
- 241000588724 Escherichia coli Species 0.000 description 23
- 238000003776 cleavage reaction Methods 0.000 description 23
- 230000007017 scission Effects 0.000 description 23
- 239000002585 base Substances 0.000 description 21
- 241000235058 Komagataella pastoris Species 0.000 description 20
- 238000012545 processing Methods 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 19
- 108091026890 Coding region Proteins 0.000 description 18
- 238000002835 absorbance Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 102100033468 Lysozyme C Human genes 0.000 description 17
- 239000000499 gel Substances 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 17
- 238000011218 seed culture Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 206010046865 Vaccinia virus infection Diseases 0.000 description 16
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 16
- 102000040430 polynucleotide Human genes 0.000 description 16
- 108091033319 polynucleotide Proteins 0.000 description 16
- 239000002157 polynucleotide Substances 0.000 description 16
- 208000007089 vaccinia Diseases 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 230000029936 alkylation Effects 0.000 description 15
- 238000005804 alkylation reaction Methods 0.000 description 15
- 238000004925 denaturation Methods 0.000 description 15
- 230000036425 denaturation Effects 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 238000012163 sequencing technique Methods 0.000 description 15
- 229910001868 water Inorganic materials 0.000 description 15
- 229910019142 PO4 Inorganic materials 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 230000006698 induction Effects 0.000 description 14
- 239000008188 pellet Substances 0.000 description 14
- 230000009467 reduction Effects 0.000 description 14
- SBKVPJHMSUXZTA-MEJXFZFPSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 SBKVPJHMSUXZTA-MEJXFZFPSA-N 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- 108010038049 Mating Factor Proteins 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 238000006731 degradation reaction Methods 0.000 description 13
- 238000002296 dynamic light scattering Methods 0.000 description 13
- 229940088598 enzyme Drugs 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 13
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 13
- 150000003573 thiols Chemical class 0.000 description 13
- 241000206602 Eukaryota Species 0.000 description 12
- 238000010367 cloning Methods 0.000 description 12
- 230000003053 immunization Effects 0.000 description 12
- 238000002649 immunization Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 150000002482 oligosaccharides Chemical class 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 235000000346 sugar Nutrition 0.000 description 12
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 11
- 230000004988 N-glycosylation Effects 0.000 description 11
- 239000012505 Superdex™ Substances 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 230000000890 antigenic effect Effects 0.000 description 11
- 230000015556 catabolic process Effects 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 11
- 230000002163 immunogen Effects 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 229920001542 oligosaccharide Polymers 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 11
- 239000010452 phosphate Substances 0.000 description 11
- 102000003960 Ligases Human genes 0.000 description 10
- 108090000364 Ligases Proteins 0.000 description 10
- 108010014251 Muramidase Proteins 0.000 description 10
- 241000282579 Pan Species 0.000 description 10
- 239000002671 adjuvant Substances 0.000 description 10
- 238000000137 annealing Methods 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 10
- 239000000969 carrier Substances 0.000 description 10
- 238000001976 enzyme digestion Methods 0.000 description 10
- 239000004325 lysozyme Substances 0.000 description 10
- 229960000274 lysozyme Drugs 0.000 description 10
- 235000010335 lysozyme Nutrition 0.000 description 10
- 150000002772 monosaccharides Chemical class 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 238000002255 vaccination Methods 0.000 description 10
- 241000271566 Aves Species 0.000 description 9
- 108010041986 DNA Vaccines Proteins 0.000 description 9
- 229940021995 DNA vaccine Drugs 0.000 description 9
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 9
- 239000011543 agarose gel Substances 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000012410 DNA Ligases Human genes 0.000 description 8
- 108010061982 DNA Ligases Proteins 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 239000007857 degradation product Substances 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000013508 migration Methods 0.000 description 8
- 230000005012 migration Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 7
- 101710144111 Non-structural protein 3 Proteins 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 125000000837 carbohydrate group Chemical group 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 239000013592 cell lysate Substances 0.000 description 7
- 230000029087 digestion Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000002703 mutagenesis Methods 0.000 description 7
- 231100000350 mutagenesis Toxicity 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 238000003058 natural language processing Methods 0.000 description 7
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- -1 nucleotide sugars Chemical class 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 208000002109 Argyria Diseases 0.000 description 6
- 244000062995 Cassia occidentalis Species 0.000 description 6
- 101100223032 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) dapB gene Proteins 0.000 description 6
- 101150045458 KEX2 gene Proteins 0.000 description 6
- 108050000633 Lysozyme C Proteins 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 6
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 6
- 101150028158 STE13 gene Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 108090000637 alpha-Amylases Proteins 0.000 description 6
- 102000004139 alpha-Amylases Human genes 0.000 description 6
- 229940024171 alpha-amylase Drugs 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 6
- 238000010195 expression analysis Methods 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 239000013014 purified material Substances 0.000 description 6
- 239000012264 purified product Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 5
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 5
- 239000001888 Peptone Substances 0.000 description 5
- 108010080698 Peptones Proteins 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 229940041514 candida albicans extract Drugs 0.000 description 5
- 238000011210 chromatographic step Methods 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 235000019319 peptone Nutrition 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000012807 shake-flask culturing Methods 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000004448 titration Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 239000012138 yeast extract Substances 0.000 description 5
- 108090001008 Avidin Proteins 0.000 description 4
- 230000005653 Brownian motion process Effects 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 108700008783 Hepatitis C virus E1 Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 102000004856 Lectins Human genes 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 101800001020 Non-structural protein 4A Proteins 0.000 description 4
- 101800001019 Non-structural protein 4B Proteins 0.000 description 4
- 101800001014 Non-structural protein 5A Proteins 0.000 description 4
- 241000282577 Pan troglodytes Species 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 238000005273 aeration Methods 0.000 description 4
- 229940037003 alum Drugs 0.000 description 4
- 239000002518 antifoaming agent Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000005537 brownian motion Methods 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 150000002019 disulfides Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 4
- 239000002523 lectin Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 229950006780 n-acetylglucosamine Drugs 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- HAEPBEMBOAIUPN-UHFFFAOYSA-L sodium tetrathionate Chemical compound O.O.[Na+].[Na+].[O-]S(=O)(=O)SSS([O-])(=O)=O HAEPBEMBOAIUPN-UHFFFAOYSA-L 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 description 4
- 239000007222 ypd medium Substances 0.000 description 4
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 3
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 3
- NGYHUCPPLJOZIX-XLPZGREQSA-N 5-methyl-dCTP Chemical compound O=C1N=C(N)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NGYHUCPPLJOZIX-XLPZGREQSA-N 0.000 description 3
- 102000057234 Acyl transferases Human genes 0.000 description 3
- 108700016155 Acyl transferases Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101710204837 Envelope small membrane protein Proteins 0.000 description 3
- 210000000712 G cell Anatomy 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 3
- 108050008546 Hyperglycemic hormone Proteins 0.000 description 3
- 241001138401 Kluyveromyces lactis Species 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- 101710145006 Lysis protein Proteins 0.000 description 3
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 3
- 101710144128 Non-structural protein 2 Proteins 0.000 description 3
- 101710199667 Nuclear export protein Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108010076039 Polyproteins Proteins 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 229940100198 alkylating agent Drugs 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000009295 crossflow filtration Methods 0.000 description 3
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 3
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 3
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 3
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 3
- VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 229920002477 rna polymer Polymers 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 235000010265 sodium sulphite Nutrition 0.000 description 3
- 239000001119 stannous chloride Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 2
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
- QFRHEHPVTSCSIH-UHFFFAOYSA-N 2,2,2-trifluoro-n-(2-iodoethyl)acetamide Chemical compound FC(F)(F)C(=O)NCCI QFRHEHPVTSCSIH-UHFFFAOYSA-N 0.000 description 2
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 2
- 108010011619 6-Phytase Proteins 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 241000238154 Carcinus maenas Species 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- 108010087806 Carnosine Proteins 0.000 description 2
- 241000283715 Damaliscus lunatus Species 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 2
- 102100022624 Glucoamylase Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108091006054 His-tagged proteins Proteins 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 241000257303 Hymenoptera Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102000005488 Thioesterase Human genes 0.000 description 2
- 102000002933 Thioredoxin Human genes 0.000 description 2
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 108700014220 acyltransferase activity proteins Proteins 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 230000001745 anti-biotin effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 238000005311 autocorrelation function Methods 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229940044199 carnosine Drugs 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 238000013354 cell banking Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000035071 co-translational protein modification Effects 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- VLYUGYAKYZETRF-UHFFFAOYSA-N dihydrolipoamide Chemical compound NC(=O)CCCCC(S)CCS VLYUGYAKYZETRF-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 108091005608 glycosylated proteins Proteins 0.000 description 2
- 102000035122 glycosylated proteins Human genes 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000001573 invertase Substances 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 2
- 238000012317 liver biopsy Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000013411 master cell bank Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 229940085127 phytase Drugs 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229940021993 prophylactic vaccine Drugs 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000005664 protein glycosylation in endoplasmic reticulum Effects 0.000 description 2
- 235000021251 pulses Nutrition 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003958 selenols Chemical class 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000003019 stabilising effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 108020002982 thioesterase Proteins 0.000 description 2
- 108060008226 thioredoxin Proteins 0.000 description 2
- 229940094937 thioredoxin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 108010087967 type I signal peptidase Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 1
- YWXCBLUCVBSYNJ-UHFFFAOYSA-N 2-(2-sulfanylethylsulfonyl)ethanethiol Chemical compound SCCS(=O)(=O)CCS YWXCBLUCVBSYNJ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- SJMLATCMQNTURW-UHFFFAOYSA-N 2-sulfanyl-n'-(2-sulfanylacetyl)acetohydrazide Chemical compound SCC(=O)NNC(=O)CS SJMLATCMQNTURW-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- CYWHLOXWVAWMFO-UHFFFAOYSA-N 3-sulfanyl-1h-pyridine-2-thione Chemical compound SC1=CC=CN=C1S CYWHLOXWVAWMFO-UHFFFAOYSA-N 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- ZVHHSBAWAOBBSE-UHFFFAOYSA-N 6-amino-1-(4-aminophenyl)arsanylhexan-1-one Chemical compound NCCCCCC(=O)[AsH]C1=CC=C(N)C=C1 ZVHHSBAWAOBBSE-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 244000003363 Allium ursinum Species 0.000 description 1
- 235000005336 Allium ursinum Nutrition 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- BIBOEMPSFOZZEM-UFLZEWODSA-N C(C)N1C(C=CC1=O)=O.OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12 Chemical compound C(C)N1C(C=CC1=O)=O.OC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12 BIBOEMPSFOZZEM-UFLZEWODSA-N 0.000 description 1
- 241000178270 Canarypox virus Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000238155 Carcinus Species 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102100031636 Dynein axonemal heavy chain 9 Human genes 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101000658547 Escherichia coli (strain K12) Type I restriction enzyme EcoKI endonuclease subunit Proteins 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000234283 Galanthus nivalis Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000017278 Glutaredoxin Human genes 0.000 description 1
- 108050005205 Glutaredoxin Proteins 0.000 description 1
- 101150069554 HIS4 gene Proteins 0.000 description 1
- 101000575170 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) 50S ribosomal protein L12 Proteins 0.000 description 1
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000866325 Homo sapiens Dynein axonemal heavy chain 9 Proteins 0.000 description 1
- 101000957351 Homo sapiens Myc-associated zinc finger protein Proteins 0.000 description 1
- 101001033034 Homo sapiens UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 244000043158 Lens esculenta Species 0.000 description 1
- 235000010666 Lens esculenta Nutrition 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- DUKURNFHYQXCJG-UHFFFAOYSA-N Lewis A pentasaccharide Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)OC1CO DUKURNFHYQXCJG-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100038750 Myc-associated zinc finger protein Human genes 0.000 description 1
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 description 1
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 1
- 241001532689 Narcissus pseudonarcissus Species 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000311088 Schwanniomyces Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102100038413 UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase Human genes 0.000 description 1
- LUEWUZLMQUOBSB-UHFFFAOYSA-N UNPD55895 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(O)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O LUEWUZLMQUOBSB-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000235017 Zygosaccharomyces Species 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000009875 biological transport Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- XIMIGUBYDJDCKI-UHFFFAOYSA-N diselenium Chemical compound [Se]=[Se] XIMIGUBYDJDCKI-UHFFFAOYSA-N 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- 150000004659 dithiocarbamates Chemical class 0.000 description 1
- 150000004662 dithiols Chemical class 0.000 description 1
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940093497 ergothioneine Drugs 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- UYQJCPNSAVWAFU-UHFFFAOYSA-N malto-tetraose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)O1 UYQJCPNSAVWAFU-UHFFFAOYSA-N 0.000 description 1
- LUEWUZLMQUOBSB-OUBHKODOSA-N maltotetraose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O[C@@H]3[C@@H](O[C@@H](O)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-OUBHKODOSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- GKTNLYAAZKKMTQ-UHFFFAOYSA-N n-[bis(dimethylamino)phosphinimyl]-n-methylmethanamine Chemical compound CN(C)P(=N)(N(C)C)N(C)C GKTNLYAAZKKMTQ-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 101150061302 och1 gene Proteins 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006697 redox regulation Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 150000003558 thiocarbamic acid derivatives Chemical class 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24223—Virus like particles [VLP]
Definitions
- the present invention relates to the general field of recombinant protein expression, purification of recombinant proteins, diagnosis of HCV infection, prophylactic treatment against HCV infection and to the prognosing/monitoring of the clinical efficiency of treatment of an individual with chronic hepatitis, or the prognosing/ monitoring of the natural disease.
- the present invention relates to the expression of hepatitis C virus envelope proteins in yeast, expression constructs for the efficient expression of HCV envelope proteins, yeast strains for the expression of core-glycosylated viral envelope proteins, purification methods for these proteins, and the use in diagnosis, prophylaxis or therapy of HCV envelope proteins purified according to the present invention,
- HCV infection is a major health problem in both developed and developing countries. It is estimated that about 1 to 5 % of the world population is affected by the virus. HCV infection appears to be the most important cause of transfusion- associated hepatitis and frequently progresses to chronic liver damage. Moreover, there is evidence implicating HCV in induction of hepatocellular carcinoma. Consequently, the demand for reliable diagnostic methods and effective therapeutic agents is high. Also sensitive and specific screening methods of HCV-contaminated blood-products and improved methods to culture HCV are needed.
- HCV is a positive stranded RNA virus of approximately 9,600 bases which encode a single polyprotein precursor of about 3000 amino acids. Proteolytic cleavage of the precursor coupled to co- and posttranslational modifications has been shown to result in at least three structural and six non-structural proteins. Based on sequence homology, the structural proteins have been functionally assigned as one single core protein and two envelope glycoproteins: El and E2.
- the El protein consists of 192 amino acids and contains 5 to 6 N-glycosylation sites, depending on the HCV genotype.
- the E2 protein consists of 363 to 370 amino acids and contains 9-11 N-glycosylation sites, depending on the HCV genotype (for reviews see: Major and Feinstone, 1997; Maertens and Stuyver, 1997).
- the El protein contains various variable domains (Maertens and Stuyver, 1997), while the E2 protein contains three hypervariable domains, of which the major domain is located at the N- terminus of the protein (Maertens and Stuyver, 1997).
- the HCN glycoproteins localize predominantly in the ER where they are modified and assembled into oligomeric complexes.
- sugar residues are commonly linked to four different amino acid residues. These amino acid residues are classified as O-linked (serine, threonine, and hydroxylysine) and ⁇ -linked (asparagine).
- O-linked sugars are synthesized in the Golgi or rough Endoplasmic Reticulum (ER) from nucleotide sugars.
- ER Endoplasmic Reticulum
- the ⁇ -linked sugars are synthesized from a common precursor, and subsequently processed. It is believed that HCN envelope proteins are ⁇ -glycosylated.
- the oligosaccharide is further processed into the complex type (containing ⁇ - acetylglucosamine, mannose, fucose, galactose and sialic acid) or the high-mannose type (containing ⁇ -acetylglucosamine and mannose).
- HCN envelope proteins are believed to be of the high-mannose type.
- ⁇ -linked oligosaccharide processing in yeast is very different from mammalian Golgi processing. In yeast the oligosaccharide chains are elongated in the Golgi through stepwise addition of mannose, leading to elaborate high mannose structures, which do not contain sialic acid. In contrast therewith, proteins expressed in prokaryotes are never glycosylated.
- HCN antigenic determinants should be identified, and administered to patients in a proper setting.
- Antigenic determinants can be divided in at least two forms, i.e. lineair and conformational epitopes. Conformational epitopes result from the folding of a molecule in a three-dimensional space, including co- and posttranslational modifications, such as glycosylation.
- HCN envelope proteins have been produced by recombinant techniques in Escherichia coli, insect cells, yeast cells and mammalian cells. However, expression in higher eukaryotes has been characterised by the difficulty of obtaining large amounts of antigens for eventual vaccine production. Expression in prokaryotes, such as E. coli results in HCN envelope proteins that are not glycosylated. Expression of HCN envelope proteins in yeast resulted in hyperglycosylation. As already demonstrated in WO 96/04385, the expression of HCN envelope protein E2 in Saccharomyces cerevisiae leads to proteins which are heavily glycosylated. This hyperglycosylation leads to shielding of protein epitopes. Although Mustilli et al.
- HCN envelope proteins derived from an intracellular source are well accepted (WO 96/04385 to Maertens et al. and Heile et al., 2000). This result is exemplified by the poor reactivity of this material with sera of chimpanzee immunized with mammalian cell culture derived E2 protein (see Figure 5). This is further documented by Rosa and colleagues (1996) who show that immunization with yeast derived HCN envelope proteins fails to protect from challenge. Consequently, there is a need for efficient expression systems resulting in large and cost- effective amounts of HCN envelope proteins that at the same time have a nativelike glycosylation pattern.
- the present invention overcomes these problems, since it describes and makes for the first time in yeast, large amounts HCN proteins with a native-like glycosylation pattern.
- HCN El and/or HCN E2 protein expression or any part thereof, characterised in that said HCN El and/or HCN E2 proteins, or said parts thereof, are core- glycosylated.
- HCN core- glycosylated hepatitis C virus
- HCN hepatitis C virus
- a method for producing core- glycosylated hepatitis C virus (HCN) envelope proteins, or any part thereof, suitable for use in an immunoassay or vaccine comprising: (i) growing Hansenula or Saccharomyces glycosylation minus strains transformed with an envelope gene encoding an HCN El and/or HCN E2 protein, or any part thereof, in a suitable culture medium; (ii) causing expression of said HCN El and/or HCN E2 gene, or any part thereof; and (iii) purifying said core-glycosylated HCN El and/or HCN E2 protein, or any part thereof, from said cell culture, or alternatively (iii) purifying said intracellularly expressed core- glycosylated HCN El and/or HCN E2 protein, or any part thereof, upon lysing the transformed host cell.
- HCN hepatitis C virus
- HCN hepatitis C virus
- HCN El and/or HCN E2 proteins or any part thereof, according to that aims described above, for use as a medicament.
- HCN El and/or HCN E2 proteins or any part thereof, as described above, for the preparation of a diagnostic kit, or for the manufacture of a vaccine/medicament against HCN infection. It is an aim of the present invention to provide an immunoassay for detecting HCN antibody in a biological sample, which immunoassay comprises: (i) providing the HCN envelope protein, or any part thereof, according to any of the claims 1 to 10; (ii) incubating a biological sample with said HCN antibody under conditions that allow formation of HCN antibody-HCN protein complex; and (iii) determining whether said HCN antibody-HCV protein complex is formed.
- kit for detecting HCN antibody in a biological sample comprises: providing the HCN envelope protein, or any part thereof, as described above.
- Figure 1 Schematic map of the vector pGEMT-ElsH6RB which has the sequence as defined in SEQ ID NO:6.
- Figure 2. Schematic map of the vector pCHH- ⁇ ir which has the sequence as defined in
- Figure 4 Schematic map of the vector pFPMT-CHH-El-H6 which has the sequence as defined in SEQ ID NO: 13.
- Figure 5 Schematic map of the vector pFPMT-MFa-El-H6 which has the sequence as defined in SEQ ID NO: 16.
- Figure 6 Schematic map of the vector pUC18-FMD ⁇ MFa-El-H6 which has the sequence as defined in SEQ ID NO: 17.
- Figure 7. Schematic map of the vector pUC18-FMD-CL-El-H6 which has the sequence as defined in SEQ ID NO:20.
- Figure 8 Schematic map of the vector pFPMT-CL-El-H6 which has the sequence as defined in SEQ ID NO:21.
- Figure 9 Schematic map of the vector pSP72E2H6 which has the sequence as defined in SEQ ID NO:22.
- FIG. 10 Schematic map of the vector pMPT121 which has the sequence as defined in
- Figure 11 Schematic map of the vector pFPMT-MFa-E2-H6 which has the sequence as defined in SEQ ID NO:24.
- Figure 12. Schematic map of the vector pMPT-MFa-E2-H6 which has the sequence as defined in SEQ ID NO:25.
- Figure 14 Schematic map of the vector pFPMT-CL-E2-H6 which has the sequence as defined in SEQ ID NO:32.
- Figure 15 Schematic map of the vector pUC18-FMD-CL-El which has the sequence as defined in SEQ ID NO:35.
- Figure 16 Schematic map of the vector pFPMT-CL-El which has the sequence as defined in SEQ ID NO:36.
- Figure 17. Schematic map of the vector pUC18-FMD-CL-H6-El-K-H6 which has the sequence as defined in SEQ ID NO:39.
- Figure 18 Schematic map of the vector pFPMT-CL-H6-K-El which has the sequence as defined in SEQ ID NO:40.
- Figure 19 Schematic map of the vector pYIG5 which has the sequence as defined in SEQ
- Figure 20 Schematic map of the vector pYIG5ElH6 which has the sequence as defined in
- Figure 21 Schematic map of the vector pSYl which has the sequence as defined in SEQ ID NO:43.
- Figure 22 Schematic map of the vector pSYlaMFElsH6a which has the sequence as defined in SEQ ID NO:44.
- Figure 23 Schematic map of the vector pBSK-E2sH6 which has the sequence as defined in SEQ ID NO:45.
- Figure 24 Schematic map of the vector pYIG5HCCL-22aH6 which has the sequence as defined in SEQ ID NO:46.
- Figure 25 Schematic map of the vector pYYIGSE2H6 which has the sequence as defined in SEQ ID NO:47.
- Figure 26 Schematic map of the vector pYIG7 which has the sequence as defined in SEQ ID NO:48.
- Figure 27 Schematic map of the vector pYIG7El which has the sequence as defined in
- Figure 28 Schematic map of the vector pSYlYIG7Els which has the sequence as defined in SEQ ID NO:50.
- Figure 29 Schematic map of the vector pPICZalphaA which has the sequence as defined in SEQ ID NO:51.
- Figure 30 Schematic map of the vector pPICZalphaD' which has the sequence as defined. in SEQ ID NO:52.
- Figure 31 Schematic map of the vector pPICZalphaE' which has the sequence as defined in SEQ ID NO:53.
- Figure 32 Schematic map of the vector pPICZalphaD 'ElsH6 which has the sequence as defined in SEQ ID NO:58.
- Figure 33 Schematic map of the vector pPICZalphaE'ElsH ⁇ which has the sequence as defined in SEQ ID NO:59.
- Figure 34 Schematic map of the vector pPICZalphaD 'E2sH6 which has the sequence as defined in SEQ ID NO:60.
- Figure 35 Schematic map of the vector pPICZalphaE'E2sH6 which has the sequence as defined in SEQ ID NO:61.
- Figure 36 Schematic map of the vector pUCl 8MFa which has the sequence as defined in
- FIG. 37 Elution profile of size exclusion chromatography of IMAC-purified E2-H6 protein expressed from the MF ⁇ -E2-H6-expressing Hansenula polymorpha (see Example
- the X-axis indicates the elution volume (in mL).
- the vertical lines through the elution profile indicate the fractions collected.
- "P2" pooled fractions 30 to 35
- the Y-axis indicates absorbance given in mAU (milli absorbance units).
- the X-axis indicates the elution volume in mL.
- Figure 37 were pooled and alkylated. Thereafter, the protein material was subjected to Endo H treatment for deglycosylation. Untreated material and Endo H-treated material were separated on an SDS-PAGE gel and blotted to a PVDF membrane. The blot was stained with amido black.
- Lane 1 Alkylated E2-H6 before Endo H-treatment
- Lane 2 Alkylated E2-H6 after Endo H-treatment.
- Figure 40 Western-blot analysis of cell lysates of El expressed in Saccharomyces cerevisiae. The Western-blot was developed using the El -specific monoclonal antibody
- Lanes 1-4 expression product after 2, 3, 5 or 7 days expression, respectively, in a
- Saccharomyces clone transformed with pSYlYIG7Els (SEQ ID NO:50, Figure 28) comprising the nucleotide sequence encoding the chicken lysozyme leader peptide joined to E1-H6.
- Lanes 5-7 expression product after 2, 3 or 5 days expression, respectively, in a
- Saccharomyces clone transformed with pSYlaMFElsH ⁇ aYIGl (SEQ ID NO:44, Figure 22) comprising the nucleotide sequence encoding the ⁇ -mating factor leader peptide joined to El-H6.
- Lane 8 molecular weight markers with sizes as indicated.
- Lane 9 purified Els produced by HCV-recombinant vaccinia virus-infected mammalian cells.
- FIG 41 Analysis of the immobilized metal ion affinity chromatography (IMAC)- purified E2-H6 protein expressed by and processed from CL-E2-H6 to E2-H6 by H. polymorpha (see Example 17). Proteins in different wash fractions (lanes 2 to 4) and elution fractions (lanes 5 to 7) were analyzed by reducing SDS-PAGE followed by silver staining of the gel (A, top picture) or by western blot using using a specific monoclonal antibody directed against E2 (B, bottom picture). The sizes of the molecular mass markers are indicated at the left.
- IMAC immobilized metal ion affinity chromatography
- Figure 42 Elution profile of the first IMAC chromatography step on a Ni-IDA column (Chelating Sepharose FF loaded with Ni 2+ , Pharmacia) for the purification of the sulfonated H6-K-E1 protein produced by H. polymorpha (see Example 18).
- the column was equilibrated with buffer A (50 mM phosphate, 6 M GuHCl, 1 % Empigen BB (v/v), pH 7.2) supplemented with 20 mM imidazole. After sample application, the column was washed sequentially with buffer A containing 20 mM and 50 mM imidazole, respectively (as indicated on chromatogram).
- a further washing and elution step of the His-tagged products was performed by the sequential application of buffer B (PBS, 1% empigen BB, pH 7.2) supplemented with 50 mM imidazole and 200 mM imidazole respectively (as indicated on chromatogram). Following fractions were pooled: the wash pool 1 (fractions 8 to 11, wash with 50 mM imidazole). The eluted material was collected as separate fractions 63 to 72 or an elution pool (fractions 63 to 69) was made.
- the Y-axis indicates absorbance given in mAU (milli absorbance units).
- the X-axis indicates the elution volume in mL
- FIG 43 Analysis of the IMAC-purified H6-K-E1 protein (see Figure 42) expressed by and processed from CL-H6-K-E1 to H6-K-E1 by H. polymoipha. Proteins in the wash pool 1 (lane 12) and elution fractions 63 to 72 (lanes 2 to 11) were analyzed by reducing SDS- PAGE followed by silver staining of the gel (A, top picture). Proteins present in the sample before IMAC (lane 2), in the flow-through pool (lane 4), in wash pool 1 (lane 5) and in the elution pool (lane 6) were analyzed by western blot using a specific monoclonal antibody directed against El (IGH201) (B, bottom picture; no sample was loaded in lane 3).
- IGH201 a specific monoclonal antibody directed against El
- FIG 45 Western-blot analysis indicating specific Els proteins bands reacting with biotinylated heparin (see also Example 19).
- Els preparations purified from HCV- recombinant vaccinia virus-infected mammalian cell culture or expressed by H. polymorpha were analyzed.
- the panel right from the vertical line shows a Western-blot developed with the biotinylated El specific monoclonal IGH 200.
- the panel left from the vertical line shows a Western-blot developed with biotinylated heparin. From these results it is concluded that mainly the lower-glycosylated Els has high affinity for heparin.
- Lanes M molecular weight marker (molecular weights indicated at the left).
- Lanes 1 Els from mammalian cells and alkylated during isolation. Lanes 2: Els-H6 expressed by H. polymorpha and sulphonated during isolation. Lanes 3: Els-H6 expressed by H. polymorpha and alkylated during isolation. Lanes 4: same material as loaded in lane 2 but treated with dithiotreitol to convert the sulphonated Cys-thiol groups to Cys-thiol.
- FIG. 46 Size exclusion chromatography (SEC) profile of the purified H. polymorpha- expressed E2- ⁇ 6 in its sulphonated form, submitted to a run in PBS, 3% betain to force virus-like particle formation by exchange of Empigen BB for betain.
- the pooled fractions containing the NLPs used for further study are indicated by " «- ".
- the Y-axis indicates absorbance given in mAU (milli absorbance units).
- the X-axis indicates the elution volume in mL. See also Example 20.
- FIG. 47 Size exclusion chromatography (SEC) profile of the purified H. polymorpha- expressed E2-H6 in its alkylated form, submitted to a run in PBS, 3% betain to force viruslike particle formation by exchange of Empigen BB for betain.
- the pooled fractions containing the NLPs are indicated by " ⁇ ->”.
- the Y-axis indicates absorbance given in mAU (milli absorbance units).
- the X-axis indicates the elution volume in L. See also Example 20.
- FIG 48 Size exclusion chromatography (SEC) profile of the purified H. polymorpha- expressed El in its sulphonated form, submitted to a run in PBS, 3% betain to force virus- like particle formation by exchange of Empigen BB for betain.
- the pooled fractions containing the NLPs are indicated by "- -”.
- the Y-axis indicates absorbance given in mAU (milli absorbance units).
- the X-axis indicates the elution volume in mL. See also Example 20.
- Figure 49 Size exclusion chromatography (SEC) profile of the purified H.
- Figure 52 Hansenula-produced El was alkylated ("A") or sulphonated (“S”) and coated on a ELISA solid support to determine the end point titer of antibodies present in sera after vaccination of mice with Hansenula-produced El that was alkylated (top panel), or after vaccination of mice with Hansenula-p ⁇ o ⁇ ace ⁇ El that was sulphonated (bottom panel).
- the horizontal bar represents the mean antibody titer.
- the end-point titers (fold-dilution) are indicated on the Y-axis. See also Example 23.
- FIG. 53 HCN El produced by HCN-recombinant vaccinia virus-infected mammalian cells and HCN El produced by H. polymoipha were coated directly to ELISA plates. End point titers of antibodies were deteremined in sera of chimpanzees vaccinated with El produced by mammalian cells (top panel) and of murine monoclonal antibodies raised against El produced by mammalian cells (bottom panel). Chimpanzees Yoran and Marti were prophylactically vaccinated. Chimpanzees Ton, Phil, Marcel, Peggy and Femma were
- Figure 54 Fluorophore-assisted carbohydrate gelelectrophoresis of oligosaccharides released from El produced by recombinant vaccinia virus-infected mammalian cells and from E 1 -H6 protein produced by Hansenula.
- Lane 1 Glucose ladder standard with indication at the left of the number of monosaccharides (3 to 10, indicated by G3 to G10).
- Lane 2 25 ⁇ g N-linked oligosaccharides released from (alkylated) El produced by mammalian cells.
- Lane 3 25 ⁇ g N- linked oligosaccharides released from (alkylated) E1-H6 produced by
- the present invention relates to HCN envelope proteins that have a native-like glycosylation pattern, while being expressed in yeast.
- HCV envelope proteins relates to a polypeptide or an analogue thereof (e.g. mimotopes) comprising an amino acid sequence (and/or amino acid analogues) defining at least one HCV epitope of either the El or the E2 region, in addition to a glycosylation site.
- These envelope proteins may be both monomeric, hetero-oligomeric or homo-oligomeric forms of recombinantly expressed envelope proteins.
- sequences defining the epitope correspond to the amino acid sequences of either the El or the E2 region of HCV (either identically or via substitutions of analogues of the native amino acid residue that do not destroy the epitope). It will be understood that the HCV epitope may co-locate with the glycosylation site.
- the epitope-defining sequence will be 3 or 4 amino acids in length, more typically, 5, 6, or 7 amino acids in length, more typically 8 or 9 amino acids in length, and even more typically 10 or more amino acids in length.
- the length of the epitope-defining sequence can be subject to wide variations, since it is believed that these epitopes are formed by the three-dimensional shape of the antigen (e.g. folding).
- the amino acids defining the epitope can be relatively few in number, but widely dispersed along the length of the molecule being brought into the correct epitope conformation via folding.
- the portions of the antigen between the residues defining the epitope may not be critical to the conformational structure of the epitope.
- a conformational epitope may also be formed by 2 or more essential regions of subunits of a homo-oligomer or hetero-oligomer.
- the HCV antigens of the present invention comprise conformational epitopes from the El and/or E2 (envelope) domains of HCV.
- the El domain which is believed to correspond to the viral envelope protein, is currently estimated to span amino acids 192-383 of the HCV polyprotein (Hijikata et al., 1991).
- the E2 protein previously called NS1, is believed to span amino acids 384-809 or 384-746 (Grakoui et al., 1993) of the HCV polyprotein and also to be an envelope protein.
- the E2 protein may also be expressed together with the El, and/or core (aa 1-191), and/or P7 (aa 747-809), and/or NS2 (aa 810-1026), and/or NS3 (aa 1027-1657), and/or NS4A (aa 1658-1711) and/or NS4B (aa 1712-1972) and/or NS5A (aa 1973-2420), and/or NS5B (aa 2421-3011).
- the El protein may also be expressed together with the E2, and/or core (aa 1-191), and/or P7 (aa 747-809), and/or NS2 (aa 810-1026), and/or NS3 (aa 1027-1657), and/or NS4A (aa 1658- 1711) and/or NS4B (aa 1712-1972), and/or NS5A (aa 1973-2420), and or NS5B (aa 2421- 3011). Expression together with these other HCV proteins may be important for obtaining the correct protein folding.
- the term 'El' as used herein also includes analogs and truncated forms that are immunologically cross-reactive with natural El, and includes El proteins of genotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or any other newly identified HCV type or subtype.
- the term 'E2' as used herein also includes analogs and truncated forms that are immunologically cross- reactive with natural E2, and includes E2 proteins of genotypes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or any other newly identified HCV type or subtype. For example, insertions of multiple codons between codon 383 and 384, as well as deletions of amino acids 384-387 have been reported by Kato et al. (1992).
- HCV proteins that are co-expressed with the HCV envelope proteins of the present invention can be derived from any HCV type, thus also from the same type as the HCV envelope proteins of the present invention.
- 'E1/E2' refers to an oligomeric form of envelope proteins containing at least one El component and at least one E2 component.
- the term 'specific oligomeric 1 El and/or E2 and/or E1/E2 envelope proteins refers to all possible oligomeric forms of recombinantly expressed El and/or E2 envelope proteins which are not aggregates. El and/or E2 specific oligomeric envelope proteins are also referred to as homo-oligomeric El or E2 envelope proteins (see below).
- the term 'single or specific oligomeric' El and/or E2 and/or E1/E2 envelope proteins refers to single monomeric El or E2 proteins (single in the strict sense of the word) as well as specific oligomeric El and/or E2 and/or E1/E2 recombinantly expressed proteins.
- 'homo-oligomer' refers to a complex of El or E2 containing more than one El or E2 monomer, e.g. El/El dimers, El/El/El trimers or E1/E1/E1/E1 tetramers and E2/E2 dimers, E2/E2/E2 trimers or E2/E2/E2/E2 tetramers, El pentamers and hexamers, E2 pentamers and hexamers or any higher-order homo-oligomers of El or E2 are all 'homo- oligomers' within the scope of this definition.
- the oligomers may contain one, two, or several different monomers of El or E2 obtained from different types or subtypes of hepatitis C virus including for example those described in an international application published under WO 94/25601 and European application No. 94870166.9 both by the present applicants.
- Such mixed oligomers are still homo-oligomers within the scope of this invention, and may allow more universal diagnosis, prophylaxis or treatment of HCV.
- the El and E2 antigens used in the present invention may be full-length viral proteins, substantially full-length versions thereof, or functional fragments thereof (e.g. fragments comprising at least one epitope and/or glycosylation site).
- the HCV antigens of the present invention can also include other sequences that do not block or prevent the formation of the conformational epitope of interest.
- the presence or absence of a conformational epitope can be readily determined through screening the antigen of interest with an antibody (polyclonal serum or monoclonal to the conformational epitope) and comparing its reactivity to that of a denatured version of the antigen which retains only linear epitopes (if any). In such screening using polyclonal antibodies, it may be advantageous to adsorb the polyclonal serum first with the denatured antigen and see if it retains antibodies to the antigen of interest.
- protein' refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and polypeptides are included within the definition of protein. This term also does not refer to or exclude post-expression modifications of the protein, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogues of an amino acid (including, for example, unnatural amino acids, PNA, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.
- the proteins of the present invention are glycosylated.
- Glycosylated proteins intend proteins that contain one or more carbohydrate groups, in particular sugar groups. In general, all eukaryotic cells are able to glycosylate proteins.
- HCV subtype lb El protein contains 6 glycosylation sites, but some of these glycosylation sites are absent in certain other (sub)types.
- the fourth carbohydrate motif (on Asn250), present in types lb, 6a, 7, 8, and 9, is' absent in all other types know today.
- This sugar-addition motif may be mutated to yield a type lb El protein with improved reactivity.
- the type 2b sequences show an extra glycosylation site in the V5 region (on Asn299).
- the isolate S83, belonging to genotype 2c even lacks the first carbohydrate motif in the VI region (on Asn), while it is present on all other isolates (Stuyver et al., 1994)
- the presence of the carbohydrate may not be required for folding, but may have a role in evasion of immune surveillance.
- the identification of the role of glycosylation can be further tested by mutagenesis of the glycosylation motifs.
- Mutagenesis of a glycosylation motif can be achieved by either mutating the codons for N, S, or T, in such a way that these codons encode amino acids different from N in the case of N, and/or amino acids different from S or T in the case of S and in the case of T.
- the X position may be mutated into P, since it is known that NPS or NPT are not frequently modified with carbohydrates.
- glycosylation refers to N-glycsoylation unless otherwise specified.
- the present invention relates to HCV envelope proteins, or parts thereof that are core-glycosylated.
- core-glycosylation refers to a structure "similar” to the structure as described by Herscovics and Orlean (1993) in Figure 3 (boxed structure).
- the carbohydrate structure referred to contains 10 mono-saccharides.
- said disclosure is herein incorporated by reference.
- similar intends that not more than about 5 additional mono-saccharides have been added to the structure or that not more than about 3 mono-saccharides have been removed from the structure.
- a carbohydrate structure consists most preferentially of 10 mono- saccharides, but minimally of 7, and more preferentially of 8 or 9 mono-sacchariden, and maximally of 15 mono-saccharides, and more preferentially of 14, 13, 12, or 11 mono- saccharides.
- the mono-saccharides connoted are preferentially glucose, mannose or N- acetyl glucosamine.
- signal sequence intends an amino acid sequence that targets a protein to the rough ER and is in this way a prerequisite for N-glycosylation.
- the signal sequence is cleaved off on the luminal side of this ER by host specific proteases referred to as signal peptidases.
- the signal sequence of this invention is correctly removed from HCV envelope proteins by a yeast signal peptidase.
- the preferrred signal sequence is the signal sequence of lysozyme C (CL-leader; 1,4-beta-N-acetylmuramidase C, EC 3.2.1.17), which has the amino acid sequence as set forth in SEQ ID NO.T. It is understood that the amino acids of this sequence may be exchanged for others without affecting the functionality, i.e. functional equivalent, which targets HCV envelope proteins to the rough ER, as evidenced by the presence of N-glycosylation of these HCV envelope proteins and the signal sequence being correctly cleaved off.
- the present invention relates to "correctly processed” HCV envelope proteins, when expressed in yeast.
- the term “correctly processed” connotes that at least about 40%, but more preferentially about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 91%, 98% or even 99% of the glycoproteins of the present invention is cleaved at exactly the intended site, i.e. that the complete signal sequence is removed, but only the signal sequence.
- the glycosylated envelope proteins of the present invention may still be purified provided sufficiently discriminating biochemical characteristics between the different expression products exist.
- the present invention relates to a method for purifying core glycosylated hepatitis C virus (HCV) envelope proteins, or any part thereof, suitable for use in an immunoassay or vaccine as described above, in which the HCV envelope gene, or any part thereof, contains a CL-leader or a functional equivalent thereof.
- HCV core glycosylated hepatitis C virus
- the present invention relates to the use of the CL leader, or a functionally equivalent thereof, for the expression of viral envelope proteins in yeast
- the present invention relates to a vector suitable for transformation of a yeast and comprising an expression cassette comprising a DNA sequence encoding for a viral envelope protein preceeded by the CL leader, or a functionally equivalent thereof.
- the present invention relates to a host organism transformed with the vector as described above.
- HCV envelope proteins of the present invention may be achieved by a number of methods. For example, one may express the HCV envelope proteins of the present invention in lower eukaryotes (such as yeast). Other host organisms include higher eukaryotes, such as mammalian cells.
- lower eukaryotes such as yeast
- Other host organisms include higher eukaryotes, such as mammalian cells.
- Host organsims such as lower eukaryotes, in particular yeast
- vectors which may replicate within the host cell independently, or may integrate into the host cell genome.
- These vectors usually contain selection markers such as URA3, LEU2,
- the vector also contains an 'expression cassette' which comprises a promoter, a leader sequence, a coding sequence of interest and a transcription termination sequence.
- an 'expression cassette' which comprises a promoter, a leader sequence, a coding sequence of interest and a transcription termination sequence.
- Procedures to transform yeast usually vary with the yeast species but are well known in the art and include electroporation, spheroplast transformation and lithium acetate or other alkali cation transformations.
- HCV envelope proteins or the parts thereof, upon lysing the transformed host cell. Lysis of the transformed host cells can be accomplished by a variety of techniques known in the art.
- the transformed host cells are subjected to a freeze-thaw cycle followed by resuspension in a solution containing a chaotropic agent, such as, for example, in 6M
- the terms “expressed” and “recombinantly expressed” are used interchangeably herein.
- the terms “expressed” and “recombinantly expressed” used within the context of the present invention refers to the fact that the proteins of the present invention are produced by recombinant expression methods in lower eukaryotes. Expression techniques are well known in the art, such as for example described in Sambrook et al (1989).
- the term 'lower eukaryote' refers to host cells such as yeast, fungi and the like. Lower eukaryotes are generally (but not necessarily) unicellular.
- Preferred lower eukaryotes are yeasts, particularly species within Saccharomyces, S chizosaccharomyces, Kluyveromyces, Pichia (e.g. Pichia pastoris), Hansenula (e.g. Hansenula polymorpha), Yarowia, Schwaniomyces, Schizo- saccharomyces, Zygosaccharomyces and the like.
- the present invention contemplates in particular Saccharomyces cerevisiae and Hansenula as convenient yeast hosts.
- yeast glycosylation minus strains, and even more preferentially Saccharomyces glycosylation minus strains are used in the present invention.
- Glycosylation minus strains are defined as strains carrying a mutation, in which the nature of the mutation is not necessarily known, but that result in a glycosylation of glycoproteins comparable to the glycosylation in Hansenula. In particular, it is contemplated that glycosylation minus strains carry a mutation, that result in a significant shift in mobility on PAGE of the invertase protein. Invertase is a protein which is normally present in Saccharomyces in a hyperglycosylated form only (Ballou et al 1991). Glycosylation minus strains include mnn2, and/or OCH1 and/or mnn9 deficient strains.
- the term 'higher eukaryote' refers to host cells derived from higher animals, such as mammals, reptiles, insects, and the like.
- Presently preferred higher eukaryote host cells are derived from Chinese hamster (e.g. CHO), monkey (e.g. COS and Vero cells), baby hamster kidney (BHK), pig kidney (PK15), rabbit kidney 13 cells (RK13), the human osteosarcoma cell line 143 B, the human cell line HeLa and human hepatoma cell lines like Hep G2, and insect cell lines (e.g. Spodoptera frugiperda).
- the host cells may be provided in suspension or flask cultures, tissue cultures, organ cultures and the like.
- the host cells may also be transgenic animals.
- the present invention relates to the use of Hansenula for HCV El and/or HCV E2 protein expression, or any part thereof, characterised in that said HCV El and/or HCV E2 proteins, or said parts thereof, are core-glycosylated.
- the present invention relates to the use of Hansenula polymorpha for the expression of viral envelope proteins which become core-glycosylated upon expression in this yeast species.
- the present invention relates to the use of Saccharomyces glycosylation minus strains for HCV El and/or HCV E2 protein expression, or any part thereof, characterised in that said HCV El and/or HCV E2 proteins, or said parts thereof, are core- glycosylated.
- the term 'purified' as applied to proteins herein refers to a composition wherein the desired protein comprises at least 35% of the total protein component in the composition.
- the desired protein preferably comprises at least 40%, more preferably at least about 50%, more preferably at least about 60%, still more preferably at least about 70%, even more preferably at least about 80%, even more preferably at least about 90%, and most preferably at least about 95%) of the total protein component.
- the composition may contain other compounds such as carbohydrates, salts, lipids, solvents, and the like, withouth affecting the determination of the percentage purity as used herein.
- An 'isolated' HCV protein intends an HCV protein composition that is at least 35% pure.
- the term 'essentially purified proteins' refers to proteins purified such that they can be used for in vitro diagnostic methods and as a therapeutic compound. These proteins are substantially free from cellular proteins, vector-derived proteins or other HCV viral components.
- these proteins are purified to homogeneity (at least 80% pure, preferably, 90%, more preferably 95%, more preferably 97%, more preferably 98%, more preferably 99%, even more preferably 99.5%, and most . preferably the containinating proteins should be undetectable by conventional methods like SDS-PAGE and silver staining.
- the cysteine residues of the HCV envelope proteins or the parts thereof, of the present invention are protected during the purification procedure. This protection can be via irreversible or via reversible protection.
- specific reference is made to the purification protocols as employed and described extensively in WO 99/67285 and WO96/04385, which are herein incorporated specifically by reference.
- the invention connotes that HCV envelope proteins as described herein, wherein at least one cysteine residue, but preferably 2 or more of the HCV envelope protein as described above can be irreversibly protected by chemical or enzymatic means.
- irreversible protection by chemical means refers to alkylation, preferably alkylation of the HCV envelope proteins by means of alkylating agents, such as, for example, active halogens, ethylenimine or N-(iodoethyl)trifluoro-acetamide.
- Alkylation can be performed by any method known in the art, such as, for example, active halogens X(CH 2 ) n R in which X is a halogen such as I, Br, Cl or F.
- active halogens are methyliodide, iodoacetic acid, iodoacetamide, and 2-bromoemylamine.
- Other methods of alkylation include the use of NEM (N-ethylmaleimide) or Biotin-NEM, a mixture thereof, or ethylenimine or N- (iodoethyl)trifluoroacetamide both resulting in substitution of -H by -CH 2 -CH 2 -NH 2 (Hermanson, 1996).
- alkylating agents refers to compounds which are able to perform alkylation as described herein. Such alkylations finally result in a modified cysteine, which can mimic other aminoacids. Alkylation by an ethylenimine results in a structure resembling lysine, in such a way that new cleavage sites for trypsine are introduced (Hermanson 1996). Similarly, the usage of methyliodide results in an amino acid resembling methionine, while the usage of iodoacetate and iodoacetamide results in amino acids resembling glutamic acid and glutamine, respectively. In analogy, these amino acids are preferably used in direct mutation of cysteine.
- the present invention pertains to HCV envelope proteins as described herein, wherein at least one cysteine residue of the HCV envelope protein as described herein is mutated to a natural amino acid, preferentially to methionine, glutamic acid, glutamine or lysine.
- mutated refers to site-directed mutagenesis of nucleic acids encoding these amino acids, ie to the well kown methods in the art, such as, for example, site-directed mutagenesis by means of PCR or via oligonucleotide-mediated mutagenesis as described in Sambrook et al. (1989).
- alkylation refers to the use of iodo-acetamide as an alkylating agent unless otherwise specified.
- cysteine residues of the HCV proteins or the parts thereof of the present invention can reversibly protected.
- the purpose of reversibly protection is to stabilise the HCV protein.
- sulfur-containing functional group eg thiols and disulfides
- the sulfur-containing functional group is retained in a non-reactive condition. The sulfur-containing functional group is thus unable to react with other compounds, e.g. no tendency of forming or exchanging disulfide bonds, such as, for example R ⁇ -SH + R 2 -SH -x-> RrS-S-R 2 ;
- the described reactions between thiols and/or disulphide residues are not limited to intermolecular processes, but may also occur intramolecularly.
- the term "reversibly protecting” as used herein contemplates covalently binding of modification agents to the cysteine residue, as well as manipulating the environment of the HCV protein such, that the redox state of the thiol-groups remains unaffected throughout subsequent steps of the purification procedure (shielding). Reversible protection of the cysteine residues can be carried out chemically or enzymatically.
- reversible protection by enzymatical means contemplates reversible protection mediated by enzymes, such as for example acyl-transferases, e.g. acyl-transferases that are involved in catalysing thio-esterification, such as palmitoyl acyltransferase (see below and Das et al., 1997).
- enzymes such as for example acyl-transferases, e.g. acyl-transferases that are involved in catalysing thio-esterification, such as palmitoyl acyltransferase (see below and Das et al., 1997).
- Sulphonation is a reaction where thiol or cysteines involved in disulfide bridges are modified to S-sulfonate: RSH -» RS-SO 3 " (Andre Darbre ) or RS-SR- 2 RS-SO 3 " (sulfitolysis; Kumar et al, 1986).
- Reagents for sulfonation are e.g. Na 2 SO , or sodium tetrathionate.
- reagents for sulfonation are used in a concentration of 10 - 200 mM, and more preferentially in a concentration of 50 - 200 mM.
- sulfonation can be performed in the presence of a catalysator such as, for example Cu 2+ (100 ⁇ M - lmM) or cysteine (1 - 10 mM).
- the reaction can be performed under protein denaturing as well as native conditions (Kumar et al., 1985; Kumar et al, 1986).
- Thioester bond formation, or thio-esterification is characterised by: RSH + R'COX -» RS-COR' in which X is preferentially a halogenide in the compound R'CO-X.
- modification agents that reversibly modify the cysteinyls of the present invention such as, for example, by heavy metals, in particular Zn 2+> , Cd 2+ (Marts et al, 1991), mono-, dithio- and disulfide- compounds (e.g. aryl- and alkylmethanethiosulfonate, dithiopyridine, dithiomorpholine, dihydrolipoamide, Ellmann reagent, aldrothiolTM (Aldrich) (Rein et al, 1996), dithiocarbamates), or thiolation agents (e.g. gluthathion, N- Acetyl cysteine, cysteineamine).
- modification agents that reversibly modify the cysteinyls of the present invention such as, for example, by heavy metals, in particular Zn 2+> , Cd 2+ (Marts et al, 1991), mono-, dithio- and disulfide- compounds (e.g.
- Dithiocarbamate comprise a broad class of molecules possessing an R 1 R 2 NC(S)SR 3 functional group, which gives them the ability to react with sulphydryl groups.
- Thiol containing compounds are preferentially used in a concentration of 0.1 - 50 mM, more preferentially in a concentration of 1 - 50 mM, and even more preferentially in a concentration of 10-50 mM;
- modification agents that preserve the thiol status in particular antioxidantia, such as for example DTT, dihydroascorbate, vitamin s and derivates, mannitol, amino acids, peptides and derivates (e.g. histidine, ergothioneine, carnosine, methionine), gallates, hydroxyanisole, hydoxytoluene, hydroquinon, hydroxymethylphenol and their derivates in concentration range of 10 ⁇ M-10 mM, more preferentially in a concentration of 1-10 mM;
- antioxidantia such as for example DTT, dihydroascorbate, vitamin s and derivates, mannitol, amino acids, peptides and derivates (e.g. histidine, ergothioneine, carnosine, methionine), gallates, hydroxyanisole, hydoxytoluene, hydroquinon, hydroxymethylphenol and their derivates in concentration range of 10 ⁇ M-10
- thiol stabilising conditions such as, for example, (i) cofactors as metal ions (Zn 2+ , Mg 2+ ), ATP, (ii) pH control(e.g. for proteins in most cases pH ⁇ 5 or pH is preferentially thiol pK, -2; e.g. for peptides purified by Reverse Phase Chromatography at pH ⁇ 2).
- Combinations of reversible protection as described in (1), (2), (3) and (4) may result in similarly pure and refolded HCV proteins.
- combination compounds can be used, such as, for example Z103 (Zn carnosine), preferentially in a concentration of 1 - 10 mM.
- reversible protection also refers to, besides the modification groups or shielding described above, any cysteinyl protection method which may be reversed enzymatically or chemically, without disrupting the peptide backbone.
- the present invention specifically refers to peptides prepared by classical chemical synthesis (see above), in which, for example, thioester bounds are cleaved by thioesterase, basic buffer conditions (Beekman et al., 1997) or by hydroxylamine treatment (Vingerhoeds et al, 1996).
- Thiol containing HCV proteins can be purified, for example, on affinity chromatography resins which contain (1) a cleavable connector arm containing a disulfide bond (e.g. immobilised 5,5' dithiobis(2-nitrobenzoic acid) (Jayabaskaran et al., 1987) and covalent chromatography on activated thiol-Sepharose 4B (Pharmacia)) or (2) a aminohexanoyl-4- aminophenylarsine as immobilised ligand.
- affinity matrix has been used for the purification of proteins, which are subject to redox regulation and dithiol proteins that are targets for oxidative stress (Kalef et al, 1993). Reversible protection may also be used to increase the solubilisation and extraction of peptides (Pomroy & Deber, 1998)
- the reversible protection and thiol stabilizing compounds may be presented under a monomeric, polymeric or liposomic form.
- the removal of the reversibly protection state of the cysteine residues can chemically or enzymatically accomplished by e.g.: a reductant, in particular DTT, DTE, 2-mercaptoethanol, dithionite, SnCl 2 , sodium borohydride, hydroxylamine, TCEP, in particular in a concentration of 1 - 200 mM, more preferentially in a concentration of 50 - 200 mM; removal of the thiol stabilising conditions or agents by e.g.
- enzymes in particular thioesterases, glutaredoxine, thioredoxine, in particular in a concentration of 0.01 - 5 ⁇ M, even more particular in a concentration range of 0.1 - 5 ⁇ M.; - combinations of the above described chemical and/or enzymatical conditions.
- the removal of the reversibly protection state of the cysteine residues can be carried out in vitro or in vivo, e.g. in a cell or in an individual.
- cysteine residues may or may not be irreversibly blocked, or replaced by any reversible modification agent, as listed above.
- a reductant according to the present invention is any agent which achieves reduction of the sulfur in cysteine residues, e.g. "S-S" disulfide bridges, desulphonation of the cysteine residue (RS-SO 3 " -> RSH).
- An antioxidant is any reagent which preserves the thiol status or minimises "S-S” formation and/or exchanges.
- Reduction of the "S-S” disulfide bridges is a chemical reaction whereby the disulfides are reduced to thiol (-SH).
- the disulfide bridge breaking agents and methods disclosed in WO 96/04385 are hereby incorporated by reference in the present description.
- "S-S” Reduction can be obtained by (1) enzymatic cascade pathways or by (2) reducing compounds.
- Enzymes like thioredoxin, glutaredoxin are known to be involved in the in vivo reduction of disulfides and have also been shown to be effective in reducing "S-S" bridges in vitro. Disulfide bonds are rapidly cleaved by reduced thioredoxin at pH 7.0, with an apparent second order rate that is around 10 4 times larger than the corresponding rate constant for the reaction with DTT. The reduction kinetic can be dramatically increased by preincubation the protein solution with 1 mM DTT or dihydrolipoamide (Holmgren, 1979).
- Thiol compounds able to reduce protein disulfide bridges are for instance Dithiothreitol (DTT), Dithioerythritol (DTE), ⁇ -mercaptoethanol, thiocarbamates, bis(2-mercaptoethyl) sulfone and N,N'-bis(mercaptoacetyl)hydrazine, and sodium-dithionite.
- Reducing agents without thiol groups like ascorbate or stannous chloride (SnCl 2 ), which have been shown to be very useful in the reduction of disulfide bridges in monoclonal antibodies (Thakur et al., 1991), may also be used for the reduction of HCV proteins.
- Heparin is known to bind to several viruses and consequently binding to the HCV envelope has already been suggested (Garson et al., 1999).
- heparin in order to analyze potential binding of HCV envelope proteins to heparin, heparin can be biotinylated and subsequently the interaction of heparin with HCV envelope proteins can be analyzed, e.g. on microtiterplates coated with HCV envelope proteins.
- different expression systems can be scrutinized. For example, a strong binding is observed with part of the HCV El expressed in Hansenula, while binding with HCV El from mammalian cell culture is absent.
- heparin affinity chromatography relates to an immobilized heparin, which is able to specifically bind to HCV envelope proteins.
- Proteins of the high-mannose type bind agglutinins such as Lens culinaris, Galanthus nivalis, Narcissus pseudonarcissus Pisum sativum or Allium ursinum.
- N- acetylglucosamine can be bound by lectins, such as WGA (wheat germ agglutinin) and its equivalents. Therefore, one may employ lectins bound to a solid phase to separate the HCV envelope proteins of the present invention from cell culture supernatants, cell lysates and other fluids, e.g.
- the present invention relates to a method for purifying core glycosylated hepatitis C virus (HCV) envelope proteins, or any part thereof, suitable for use in an immunoassay or vaccine, which method comprising: growing Hansenula or Saccharomyces glycosylation minus strains transformed with an envelope gene encoding an HCV El and/or HCV E2 protein, or any part thereof, in a suitable culture medium; causing expression of said HCV El and/or HCV E2 gene, or any part thereof; and, purifying said core-glycosylated HCV El and/or HCV E2 protein, or any part thereof, from said cell culture.
- HCV hepatitis C virus
- the invention further pertains to a method for purifying core-glycosylated hepatitis C virus (HCV) envelope proteins, or any part thereof, suitable for use in an immunoassay or vaccine, which method comprising: growing Hansenula or Saccharomyces glycosylation minus strains transformed with an envelope gene encoding an HCV El and/or HCV E2 protein, or any part thereof, in a suitable culture medium; - causing expression of said HCV El and/or HCV E2 gene, or any part thereof; and purifying said intracellularly expressed core-glycosylated HCV El and/or HCV E2 protein, or any part thereof, upon lysing the transformed host cell.
- HCV hepatitis C virus
- the invention further pertains to a method for purifying core-glycosylated hepatitis C virus
- HCV HCV envelope proteins, or any part thereof, suitable for use in an immunoassay or vaccine, which method comprising:
- HCV El and/or HCV E2 protein or any part thereof, in a suitable culture medium, in which said HCV El and/or HCV E2 protein, or any part thereof, comprises at least two Cys-amino acids; -ii- causing expression of said HCV El and/or HCV E2 gene, or any part thereof; and
- the invention further pertains to a method for purifying core-glycosylated hepatitis C virus (HCV) envelope proteins, or any part thereof, suitable for use in an immunoassay or vaccine, which method comprising:
- the present invention specifically relates to a method for purifying recombinant core- glycosylated HCV yeast proteins, or any part thereof, as described herein, in which said purification includes heparin affinity chromatography.
- the present invention also relates to a method for purifying recombinant core- glycosylated HCV yeast proteins, or any part thereof, as described above, in which said chemical means is sulfonation.
- the present invention also relates to a method for purifying recombinant core- glycosylated HCV yeast proteins, or any part thereof, as described above, in which said reversibly protection of Cys-amino acids is exchanged for an irreversible protection by chemical and/or enzymatic means.
- the present invention also relates to a method for purifying recombinant core- glycosylated HCV yeast proteins, or any part thereof, as described above, in which said irreversible protection by chemical means is iodo-acetamide.
- the present invention also relates to a method for purifying recombinant core- glycosylated HCV yeast proteins, or any part thereof, as described above, in which said irreversible protection by chemical means is NEM or Biotin-NEM or a mixture thereof.
- polynucleotide or nucleic acid intends a polynucleotide or nucleic acid of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation : (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is linked in nature, or (3) does not occur in nature.
- 'recombinant host cells', 'host cells', 'cells', 'cell lines', 'cell cultures', and other such terms denoting micro-organisms or higher eukaryotic cell lines cultured as unicellular entities refer to cells which can be or have been, used as recipients for a recombinant vector or other transfer polynucleotide, and include the progeny of the original cell which has been transfected. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation.
- 'replicon' is any genetic element, e.g., a plasmid, a chromosome, a virus, a cosmid, etc., that behaves as an autonomous unit of polynucleotide replication within a cell; i.e., capable of replication under its own control.
- control sequence' refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and terminators; in eukaryotes, generally, such control sequences include promoters, terminators and, in some instances, enhancers.
- control sequences' is intended to include, at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences which govern secretion.
- 'promoter' is a nucleotide sequence which is comprised of consensus sequences which allow the binding of RNA polymerase to the DNA template in a manner such that mRNA production initiates at the normal transcription initiation site for the adjacent structural gene.
- Operably linked' refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.
- a control sequence 'operably linked' to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.
- An 'open reading frame' is a region of a polynucleotide sequence which encodes a polypeptide and does not contain stop codons; this region may represent a portion of a coding sequence or a total coding sequence.
- a 'coding sequence' is a polynucleotide sequence which is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation stop codon ' at the 3 ! -terminus.
- a coding sequence can include but is not limited to mRNA, DNA (including cDNA), and recombinant polynucleotide sequences.
- 'immunogenic' refers to the ability of a substance to cause a humoral and/or cellular response, whether alone or when linked to a carrier, in the presence or absence of an adjuvant.
- 'Neutralization' refers to an immune response that blocks the infectivity, either partially or fully, of an infectious agent.
- a "vaccine” or “medicament” is an immunogenic composition capable of eliciting protection against HCV, whether partial or complete, whether against acute or chronic disease.
- a vaccine may also be useful for treatment of an individual, in which case it is called a therapeutic vaccine.
- a vaccine therefore, includes HCV peptides, proteins, or polynucleotides. Protection against HCV refers in particular to humans, but refers also to non-human primates, trimera mouse (Zauberman et al., 1999), or other mammals.
- a vaccine composition comprises, in addition to an active substance, a suitable excipient, diluent, carrier and/or adjuvant which, by themselves, do not induce the production of antibodies harmful to the individual receiving the composition nor do they elicit protection.
- Suitable carriers are typically large slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric aa's, aa copolymers and inactive virus particles.
- adjuvants to enhance effectiveness of the composition include, but are not limited to: aluminium hydroxide, aluminium in combination with 3-0-deacylated monophosphoryl lipid A as described in WO 93/19780, aluminium phosphate as described in WO 93/24148, N-acetyl-muramyl-L-threonyl-D-isoglutamine as described in U.S.
- RIBI ImmunoChem Research Inc., Hamilton, MT, USA
- MPL any of the three components MPL, TDM or CWS may also be used alone or combined 2 by 2.
- the MPL may also be replaced by its synthetic analogue referred to as RIBI.529.
- adjuvants such as Stimulon (Cambridge Bioscience, Worcester, MA, USA) or SAF-1 (Syntex) may be used, as well as adjuvants such as combinations between QS21 and 3-de- O-acetylated monophosphoryl lipid A (WO94/00153), or MF-59 (Chiron), or poly[di(carboxylatophenoxy) phosphazene] based adjuvants (Virus Research Institute), or blockcopolymer based adjuvants such as Optivax (Vaxcel, Cythx) or inulin-based adjuvants, such as Algammulin and Gammalnulin (Anutech), Incomplete Freund's Adjuvant (IF A) or Gerbu preparations (Gerbu Biotechnik).
- Optivax
- a vaccine composition will further contain excipients and diluents, which are inherently non-toxic and non-therapeutic, such as water, saline, glycerol, ethanol, wetting or emulsifying agents, pH buffering substances, preservatives, and the like.
- excipients and diluents which are inherently non-toxic and non-therapeutic, such as water, saline, glycerol, ethanol, wetting or emulsifying agents, pH buffering substances, preservatives, and the like.
- a vaccine composition is prepared as an injectable, either as a liquid solution or suspension. Solid forms, suitable for solution on, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation may also be emulsified or encapsulated in liposomes for enhancing adjuvant effect.
- the polypeptides may also be incorporated into Immune Stimulating Complexes together with sapomns, for example Quil A (ISCOMS).
- Vaccine compositions comprise an immunologically effective amount of the polypeptides of the present invention, as well as any other of the above-mentioned components.
- Immunologically effective amount means that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for prevention or treatment. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of the individual to be treated (e.g.
- the amount will fall in a relatively broad range that can be determined through routine trials. Usually, the amount will vary from 0.01 to 1000 ⁇ g/dose, more particularly from 0.1 to 100 ⁇ g/dose.
- the vaccine compositions are conventionally administered parenterally, typically by injection, for example, subcutaneously or intramuscularly. Additional formulations suitable for other methods of administration include oral formulations and suppositories. Dosage treatment may be a single dose schedule or a multiple dose schedule.
- the vaccine may be administered in conjunction with other immunoregulatory agents. Therefore, the instant invention pertains to the use of an oligomeric particle as defined herein for prophylactically inducing immunity against HCV. It should be noted that a vaccine may also be useful for treatment of an individual as pointed-out above, in which case it is called a "therapeutic vaccine”.
- the present invention also relates to a composition as defined above which also comprises HCV core, El, E2, P7, NS2, NS3, NS4A, NS4B, NS5A and/or NS5B protein, or parts thereof.
- the core-glycosylated proteins El, E2, and/or E1/E2 of the present invention may, for example, be combined with other HCV antigens, such as, for example, core, P7, NS3, NS4A, NS4B, NS5A and/or NS5B.
- the purification of these NS3 proteins will preferentially include a reversible modification of the cysteine residues, and even more preferentially sulfonation of cysteines.
- the present invention also relates to the usage of a core- glycosylated envelope proteins as defined above or a composition as defined above for the manufacture of an HCV vaccine composition.
- the present invention relates to the usage of a core-glycosylated envelope protein as defined herein for inducing immunity against HCV in chronic HCV carriers.
- the present invention relates to the usage of a core-glycosylated envelope protein as defined herein for inducing immunity against HCV in chronic HCV carriers prior to, simultaneously to or after any other therapy, such as, for example, the well-known interferon therapy either or not in combination with the administration of small drugs treating HCV, such as, for example, ribavirin.
- a core-glycosylated envelope protein as defined herein for inducing immunity against HCV in chronic HCV carriers prior to, simultaneously to or after any other therapy, such as, for example, the well-known interferon therapy either or not in combination with the administration of small drugs treating HCV, such as, for example, ribavirin.
- Such composition may also be employed before or after liver transplantation, or after presumed infection, such as, for example, needle-stick injury.
- the present invention relates to a kit containing the a core-glycosylated envelope protein of the present invention to detect HCV antibodies present in a biological sample.
- biological sample refers to a sample of tissue or fluid isolated from an individual, including but not limited to, for example, serum, plasma, lymph fluid, the external sections of the skin, respiratory intestinal, and genitourinary tracts, oocytes, tears, saliva, milk, blood cells, tumors, organs, gastric secretions, mucus, spinal cord fluid, external secretions such as, for example, excrement, urine, sperm, and the like.
- the present invention relates also to a kit for detecting HCV related T cell response, comprising the oligomeric particle or the purified single HCV envelope protein of the instant invention.
- HCV T cell response can for example be measured as described in the examples section, or as described in PCT/EP 94/03555 to Leroux-Roels et al. It should be stressed that the whole content, including all the definitions, of this document is incorporated by reference in the present application
- the present invention relates to HCV El and/or E2 proteins, or any part thereof, as described herein, for use as medicament.
- the present invention relates to the use of HCV El and/or E2 proteins, or any part thereof, as described herein, for the manufacture of a vaccine/medicament against HCV infection..
- the present invention relates to the use of a core-glycosylated envelope protein as described herein for inducing immunity against HCV, characterized in that said core- glycosylated envelope protein is used as part of a series of time and compounds.
- a series of time and compounds refers to administering with time intervals to an individual the compounds used for eliciting an immune response.
- the latter compounds may comprise any of the following components: a core-glycosylated envelope protein, HCV DNA vaccine composition, HCV polypeptides.
- a series comprises administering, either:
- an HCV antigen such as, for example, a core-glycosylated envelope protein, with time intervals, or
- an HCV antigen such as, for example, a core-glycosylated envelope protein in combination with a HCV DNA vaccine composition, in which said core- glycosylated envelope protein oligomeric particles and said HCV DNA vaccine composition, can be administered simultaneously, or at different time intervals, including at alternating time intervals, or
- a HCV DNA vaccine composition comprises nucleic acids encoding HCV envelope peptide, including E1-, E2-, El/E2-peptides, NS3 peptide, other HCV peptides, or parts of said peptides.
- said HCV peptides comprises HCV envelope peptides, including E1-, E2-, El/E2-peptides, other HCV peptides, or parts thereof.
- the term "other HCV peptides" refers to any HCV peptide or fragment thereof.
- the HCV DNA vaccine composition comprises preferentially nucleic acids encoding HCV envelope peptides.
- an HCV DNA vaccine composition comprises a plasmid vector comprising a polynucleotide sequence encoding an HCV peptide as described above, operably linked to transcription regulatory elements.
- a "plasmid vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
- Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they have been linked.
- plasmid vectors are circular double stranded DNA loops which, in their vector form, are not bound to the chromosome.
- a "polynucleotide sequence" refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA).
- DNA deoxyribonucleic acid
- RNA ribonucleic acid
- the term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs, and single (sense or antisense) and double-stranded polynucleotides.
- transcription regulatory elements refers to a nucleotide sequence which contains essential regulatory elements, such that upon introduction into a living vertebrate cell it is able to direct the cellular machinery to produce translation products encoded by the polynucleotide.
- operably linked refers to a juxtaposition wherein the components are configured so as to perform their usual function.
- transcription regulatory elements operably linked to a nucleotide sequence are capable of effecting the expression of said nucleotide sequence.
- the DNA vaccine may be delivered through a live vector such as adenovirus, canary pox virus, MVA, and the like.
- the HCV envelope proteins of the present invention, or the parts thereof, are particularly suited for incorporation into an immunoassay for the detection of HCV, and/or genotyping of HCV, for prognosing/monitoring of HCV disease, or as a therapeutic agent.
- the immunoassay methods according to the present invention utilize the HCV envelope proteins of the present invention that maintain linear (in case of peptides) and conformational epitopes, recognized by antibodies in the sera from individuals infected with HCV.
- the HCV El and E2 antigens of the present invention may be employed in virtually any assay format that employs a known antigen to detect antibodies.
- HCV conformational epitope a format that denatures the HCV conformational epitope should be avoided or adapted.
- a common feature of all of these assays is that the antigen is contacted with the body component suspected of containing HCV antibodies under conditions that permit the antigen to bind to any such antibody present in the component. Such conditions will typically be physiologic temperature, pH and ionic strenght using an excess of antigen. The incubation of the antigen with the specimen is followed by detection of immune complexes comprised of the antigen. Design of the immunoassays is subject to a great deal of variation, and many formats are known in the art. Protocols may, for example, use solid supports, or immunoprecipitation.
- assays involve the use of labeled antibody or polypeptide; the labels may be, for example, enzymatic, fluorescent, chemiluminescent, radioactive, or dye molecules.
- Assays which amplify the signals from the immune complex are also known; examples of which are assays which utilize biotin and avidin or streptavidin, and enzyme-labeled and mediated immunoassays, such as ELISA and RIA assays.
- the immunoassay may be, without limitation, in a heterogeneous or in a homogeneous format, and of a standard or competitive type. In a heterogeneous format, the polypeptide is typically bound to a solid matrix or support to facilitate separation of the sample from the polypeptide after incubation.
- solid supports examples include nitrocellulose (e.g., in membrane or microtiter well form), polyvinyl chloride (e.g., in sheets or microtiter wells), polystyrene latex (e.g., in beads or microtiter plates, polyvinylidine fluoride (known as ImmunolonTM), diazotized paper, nylon membranes, activated beads, and Protein A beads.
- nitrocellulose e.g., in membrane or microtiter well form
- polyvinyl chloride e.g., in sheets or microtiter wells
- polystyrene latex e.g., in beads or microtiter plates
- polyvinylidine fluoride e.g., polyvinylidine fluoride (known as ImmunolonTM)
- diazotized paper e.g., in beads or microtiter plates
- diazotized paper e.g., in beads or microtiter plates
- diazotized paper
- test sample is incubated with the combination of antigens in solution.
- the combination of antigens may be under conditions that will precipitate any antigen-antibody complexes which are formed.
- Both standard and competitive formats for these assays are known in the art.
- the amount of HCV antibodies in the antibody-antigen complexes is directly monitored. This may be accomplished by determining whether labeled anti- xenogeneic (e.g. anti-human) antibodies which recognize an epitope on anti-HCV antibodies will bind due to complex formation.
- labeled anti- xenogeneic e.g. anti-human
- the amount of HCV antibodies in the sample is deduced by monitoring the competitive effect on the binding of a known amount of labeled antibody (or other competing ligand) in the complex.
- Complexes formed comprising anti-HCV antibody or in the case of competitive assays, the amount of competing antibody
- unlabeled HCV antibodies in the complex may be detected using a conjugate of anti-xenogeneic Ig complexed with a label (e.g. an enzyme label).
- the reaction between the HCV antigens and the antibody forms a network that precipitates from the solution or suspension and forms a visible layer or film of precipitate. If no anti-HCV antibody is present in the test specimen, no visible precipitate is formed.
- the HCV envelope proteins, or specific parts thereof of the present invention comprised of conformational epitopes will typically be packaged in the form of a kit for use in these immunoassays.
- the kit will normally contain in separate containers the native HCV antigen, control antibody formulations (positive and/or negative), labeled antibody when the assay format requires the same and signal generating reagents (e.g. enzyme substrate) if the label does not generate a signal directly.
- the native HCV antigen may be already bound to a solid matrix or separate with reagents for binding it to the matrix. Instructions (e.g. written, tape, CD-ROM, etc.) for carrying out the assay usually will be included in the kit.
- the solid phase selected can include polymeric or glass beads, nitrocellulose, microparticles, microwells of a reaction tray, test tubes and magnetic beads.
- the signal generating compound can include an enzyme, a luminescent compound, a chromogen, a radioactive element and a chemiluminescent compound.
- enzymes include alkaline phosphatase, horseradish peroxidase and beta-galactosidase.
- enhancer compounds include biotin, anti-biotin and avidin.
- enhancer compounds binding members include biotin, anti-biotin and avidin.
- the test sample is subjected to conditions sufficient to block the effect of rheumatoid factor-like substances.
- conditions comprise contacting the test sample with a quantity of anti-human IgG to form a mixture, and incubating the mixture for a time and under conditions sufficient to form a reaction mixture product substantially free of rheumatoid factor-like substance.
- the present invention relates to the use of HCV El and/or HCV E2 proteins, or any part thereof, as described herein, for the preparation of a diagnostic kit.
- the present invention relates to an immunoassay for detecting HCV antibody in a biological sample, which immunoassay comprises: providing the HCV envelope protein, or any part thereof, as described herein; incubating a biological sample with said HCV antibody under conditions that allow formation of HCV antibody-HCV protein complex; and determining whether said HCV antibody-HCV protein complex is formed.
- the present invention relates to a kit for detecting HCV antibody in a biological sample, which kit comprises providing the HCV envelope protein, or any part thereof, as described herein.
- EXAMPLE 1 CONSTRUCTION OF pFPMT-MF ⁇ -El-H6 SHUTTLE VECTOR Plasmids for Hansenula polymorpha transformation were constructed as follows.
- the E1-H6 DNA fragment (coding for HCV type lb Els protein consisting of the amino acids 192 to 326 of Els elongated with 6 His-residues; SEQ ID NO:5) was isolated by PCR from the plasmid pGEMTElsH6 (SEQ ID NO:6; Figure 1). The following primers were used thereto:
- CHHEl-F 5'-agttactcttca . aggtatgaggtgcgcaacgtgtccg-3' (SEQ ID NO:7);
- the Eaml l04 ⁇ site is underlined, the dot marks the cleavage site.
- the bold printed bases are complementary to those of primer CHH-links.
- the non-marked bases anneal within the start region of El (192-326) in sense direction; and - CHHE1-R:
- caggrgratcctccttaatggtgatggtggtggtgcc-3' SEQ ID NO: 8
- the E ⁇ mll04I site is underlined, the dot marks the cleavage site.
- the bold printed bases are complementary to those of primer MF30-rechts.
- the bases forming the BamHl site usefull for later cloning procedures are printed in italics.
- the non-marked bases anneal in antisense direction within the end of the E1-H6 unit, including the stop codon and three additional bases between the stop codon and the Bam ⁇ l site.
- the reaction mixture was constituted as follows: total volume of 50 ⁇ L containing 20 ng of
- Program 1 was used, said program consisting of the following steps:
- denaturation 5min 95°C; 2. 10 cycles of 30 sec denaturation at 95°C, 30 sec annealing at 65°C, and 130 sec elongation at 68°C
- the acceptor fragment was made by PCR from the pCHH-Hir plasmid (SEQ ID NO:9; Figure 2) and consists of almost the complete pCHH-Hir plasmid, except that the Hir- coding sequence is not present in the PCR product. Following primers were used for this PCR:
- CHH-links 5'-agttactcttca . cctctttccaacgggtgtgtag-3' (SEQ ID NO: 10);
- the Eaml l04 ⁇ site is underlined, the dot marks the cleavage site.
- the bold printed bases are complementary to those of primer CHHE1-F.
- the non-marked bases anneal within the end of the CHH sequence in antisense direction;
- the Eaml l04 ⁇ site is underlined, the dot marks the cleavage site.
- the bold printed bases are complementary to those of primer CHHE1-R.
- the non-marked bases anneal within the pUC18 sequences behind the cloned CHH-Hirudin HL20 of pCHH-Hir, pointing away from the insert.
- the reaction mixture was constituted as follows: total volume of 50 ⁇ L containing 20 ng of pCHH-Hir, each 0.2 ⁇ M of primers CHH-links and MF30-rechts, dNTP's (each at 0.2 ⁇ M), 1 x buffer 2 (Expand Long Template PCR System; Boeringer; Cat No 1681 834), 2.5 U polymerase mix (Expand Long Template PCR System; Boeringer; Cat No 1681 834). Program 1 was as described above was used.
- E. coli XL-Gold cells were transformed with the ligation mixture and the plasmid DNA of several ampicillin-resistant colonies were analyzed by digestion with EcoRI and BamHl. A positive clone was selected and denominated as pCHH ⁇ l.
- shuttle vector pFPMT-MF ⁇ -El-H6 was generated by ligation of three fragments, said fragments being:
- the 0.454 kb PCR product giving rise to fragment No.3 was obtained by PCR using the following primers:
- primer MFa-El f-Hi 5'-aggggtaagcttggataaaaggtatgaggtgcgcaacgtgtccgggatgt-3' (SEQ ID NO: 14);
- primer E 1 back-B am 5'-agttacggatccttaatggtgatggtggtggtggtgccagttcat-3'
- reaction mixture was constituted as follows: Reaction mixture volume 50 ⁇ L, pFPMT-CHH-El-H6 (EcoRI-linearized; 15 ng/ ⁇ L), 0.5 ⁇ L; primer MFa- ⁇ l f-Hi (50 ⁇ M),
- denaturation 5 min at 95 °C 2. 29 cycles of 45 sec denaturation at 95°C, 45 sec annealing at 55°C, and 40 sec elongation at 68°C
- the resulting 0.454kb PCR product contained the codons of El (192-326) followed by six histidine codons and a "taa" stop codon, upstream flanked by the 22 3 '-terminal base pairs of the MF ⁇ prepro sequence (including the cloning relevant Hindl ⁇ l site plus a six base pairs overhang) and downstream flanked by a (cloning relevant) BamHl site and a six base pairs overhang.
- T4 DNA ligase Boehringer Mannheim has been used according to the supplier's conditions (sample volume 20 ⁇ L).
- E.coli HB101 cells were transformed with the ligation mixture and positive clones withheld after restriction analysis of the plasmids isolated from several transformants.
- a positive plasmid was selected and denominated as pFPMT-MF ⁇ -El-H6 (SEQ ID NO:16; Figure 5).
- a first step the MF ⁇ -El-H6 reading frame of pFPMT-MF ⁇ -El-H6 was subcloned into the pUC18 vector. Therefore a 1.798kb Sall/BamH ⁇ fragment of pFPMT-MF ⁇ -El-H6 (containing the FMD promo tor plus MF ⁇ -El-H6) was ligated to the SaWBam ⁇ l vector fragment of pUC18 with T4 ligase (Boehringer) accordig to the supplier's conditions. This resulted in plasmid that is depicted in Figure 6 (SEQ ID NO: 17), and further denominated as pMal2-l (pUC18-FMD-MF ⁇ -El-H6).
- the ligation mixture was used to transform E.coli DH5 ⁇ F' cells. Several ampicillin-resistant colonies were picked and analyzed by restriction enzyme digestion of plasmid DNA isolated from the picked clones. A positive clone was further analyzed by determining the DNA sequence of the MF ⁇ -El-H6 coding sequence. A correct clone was used for PCR directed mutagenesis to replace the MF ⁇ pre- pro-sequence with the codons of the avian lysozyme pre-sequence ("CL"; corresponding to amino acids 1 to 18 of avian lysozyme; SEQ ID NO:l).
- CL codons of the avian lysozyme pre-sequence
- the principle of the applied PCR- directed mutagenesis method is based on the amplification of an entire plasmid with the desired alterations located at the 5 '-ends of the primers. In downstream steps, the ends of the linear PCR product are modified prior to self-ligation resulting in the desired altered plasmid.
- the following primers were used for the PCR reaction: 1.
- primer CL hin 5 '-tgcttcctaccactagcagcactaggatatgaggtgcgcaacgtgtccggg-3 ' (SEQ ID NO:18); 2.
- primer CL her neu 5 '-tagt ⁇ ct ⁇ o-tattagtaggcttcgcatgaattcccgatgaaggcagagagcg-3 ' (SEQ ID NO: 19).
- the underlined 5 ' regions of the primers contain the codons of about half of the avian lysozyme pre-sequence.
- Primer CL her neu includes a Spel restriction site (italic).
- the non-underlined regions of the primers anneal with the codons for amino acid residues 192 to 199 of El (CL hin) or the with the "atg" start codon over the EcoRI site up to position - 19 (counted from the EcoRI site) o ⁇ FMD promoter.
- the primers are designed to amplify the complete pMal2-l thereby replacing the codons of the MF ⁇ pre-pro-sequence with the codons of the avian lysozyme pre sequence.
- the reaction mixture was constituted as follows: pUC18-FMD-Mf ⁇ - ⁇ l-H6 (pMal2-l; 1.3 ng/ ⁇ L), 1 ⁇ L; primer CL hin (100 ⁇ M), 2 ⁇ L; primer CL her neu (100 ⁇ M), 2 ⁇ L; dNTP's (all at 2.5mM), 8 ⁇ L; H 2 O, 76 ⁇ L; Expand Long Template PCR System (Boeringer; Cat No 1681 834) Buffer 2 (10 x concentrated), lO ⁇ L; Expand Long Template PCR System Polymerase mixture (1 U/ ⁇ L), 0.75 ⁇ L.
- the PCR program consisting of the following steps was applied: 1. denaturation: 15 min at 95°C 2. 35 cycles of 30 sec denaturation at 95°C, 1 min annealing at 60°C, and 1 min elongation at 72°C 3. termination at 4°C.
- the resulting PCR product was checked by agarose gel electrophoresis for its correct size (3.5 kb). Thereafter the 3'-A overhangs form the PCR product were removed by a T4 polymerase reaction resulting in blunt ends with 3'- and 5'-OH-groups. Therefore, the PCR product was treated with T4 polymerase (Boehringer; 1 U/ ⁇ L): to the remaining 95 ⁇ L of PCR reaction mix were added 1 ⁇ L T4 polymerase and 4 ⁇ L dNTP's (all at 2.5 mM). The sample was incubated for 20 min at 37°C. Subsequently, the DNA was precipitated with ethanol and taken up in 16 ⁇ L H 2 O.
- T4 polymerase Boehringer; 1 U/ ⁇ L
- the pFPMT-CL-El-H6 shuttle vector was constructed as described below.
- the 0.486kb EcoK/BamHl fragment of p27d-3 (harboring CL-El(192-326)-H6) was ligated with EcoRI ⁇ HI-digested pFPMT121 (S ⁇ Q ID NO:12, Figure 3).
- T4 ligase (Boehringer) has been used according to the supplier's recommendations.
- the DNA in the ligation sample was precipitated with ethanol and dissolved in 10 ⁇ L H 2 O.
- Plasmid clone p37-5 (pFPMT-CL- ⁇ l-H6; SEQ ID NO:21, Figure 8) showed the desired fragment sizes of 0.486kb and 6.961kb. The correct sequence of CL-E1-H6 of p37-5 was verified by sequencing.
- Plasmids for Hansenula polymorpha transformation were constructed as follows. The DNA sequence encoding the MF ⁇ -E2s (amino acids 384-673 of HCV E2)-VIEGR-His6 (SEQ ID NO:5) was isolated as a 1.331kb EcoKI/Bglll fragment from plasmid pSP72E2H6 (SEQ ID NO:22, Figure 9). This fragment was ligated with either the EcoRI/ /II-digested vectors pFPMT121 (S ⁇ Q ID NO: 12, Figure C+2) or pMPT121 (S ⁇ Q ID NO:23, Figure 10) using T4 DNA ligase (Boehringer Mamiheim) according to the supplier's recommendations. After transformation of E.
- E2-H6 amino acids 384 to 673 of HCV E2 extended with the linker peptide "VIEGR" and with 6 His residues, SEQ ID NO:5
- the used primers were denoted MF30E2/F and MF30E2/R and have the following sequences:
- - primer MF30E2/F 5'-agtcactcttca .
- aggcatacccgcgtgtcaggaggg-3' SEQ ID NO:26; the E ⁇ 7nll04I site is underlined, the dot marks the enzyme's cleavage site; the last codon of the S. occidentalis signal sequence is printed in bold; the non- marked bases anneal with the codons of ⁇ 2 (amino acids 384-390 of HCV E2);
- - primer MF30E2/R 5'-agtcactcttca .
- cagsrgatccttagtgatggtggtgatg-3' (SEQ ID NO:27; the Eaml 1041 site is underlined, the dot marks the enzyme's cleavage site; the bold printed bases are complementary to the bold printed bases of primer MF30-Rechts (see below); a BamHl site to be introduced into the construct is printed in italic; the non- marked sequence anneals with the stop codon and the six terminal His codons of E2 (384-673)-
- VIEGR-H6 (SEQ ID NO:5).
- the reaction mixture was constituted as follows: total volume of 50 ⁇ L containing 20 ng of the 1.33kb EcoKllBglll fragment of pSP72E2H6, each 0.2 ⁇ M of primers MF30E2/F and MF30E2/R, dNTP's (each 0.2 ⁇ M), lx buffer 2 (Expand Long Template PCR System; Boeringer; Cat No 1681 834), 2.5 U polymerase mix (Expand Long Template PCR System; Boeringer; Cat No 1681 834).
- the PCR program 3 consisting of the following steps was used:
- the second fragment originated from the plasmid pMF30 (SEQ ID NO:28, Figure 13), the amplicon was almost the complete pMF30 plasmid excluding the codons of the mature ⁇ - amylase of S.occidentalis, modifications relevant for cloning were introduced by primer design.
- the following set of primers was used:
- cct is complementary to the bold printed "agg" of primer MF30E2/F (see above); the non-marked and the bold printed bases anneal with the 26 terminal bases of the codons of the ⁇ -Amylase of S. occidentalis in pMF30);
- the reaction mixture was constituted as follows: total volume of 50 ⁇ L containing 20 ng of the /II-linearized ⁇ MF30, each 0.2 ⁇ M of primers MF30-Links and MF30-Rechts, dNTP's (each 0.2 ⁇ M), lx buffer 1 (Expand Long Template PCR System; Boeringer; Cat
- the E2s-H6 encoding DNA fragment and pMF30-derived acceptor plasmid obtained by PCR were controlled on their respective size by gel electrophoresis on a 1 % agarose gel.
- the PCR products were purified with a PCR product purification kit (Qiagen) according to the supplier's instructions. Subsequently the purified fragments were digested separately with Earn 110041. Ligation of the ⁇ 2s-H6 fragment with the pMF30-derived acceptor plasmid was performed by using T4 ligase (Boehringer) according to the supplier's recommendations.
- the ligation mixture was used to transform E.coli DH5 ⁇ F'cells and the plasmid DNA of several clones was analyzed by EcoRI/if ⁇ HI digestion. A positive clone was selected, its plasmid further denominated as pAMY- ⁇ 2, and utilized for further modifications as described below.
- the pAMY-E2 was subjected to PCR-directed mutagenesis in order to replace the codons of the ⁇ -amylase signal sequence with the codons of the avian lysozyme pre sequence. This is further denominated as "CL", corresponding to the first 18 amino acids of avian lysozyme ORF (SEQ ID NO:l).
- CL corresponding to the first 18 amino acids of avian lysozyme ORF (SEQ ID NO:l).
- the underlined 5 '-regions of the primers contain the DNA sequence of about half of the avian lysozyme pre sequence.
- Primer CL2 her includes Spel (italic) and EcoRI (italic, double underlined) restriction sites.
- the non-underlined regions of the primers anneal with the codons of amino acid residues 384 to 392 of ⁇ 2 (CL2 hin) or the with the "atg" start codon over the EcoRI site up to position -19 (counted from the EcoRI site) of FMD promoter.
- the primers are designed to amplify the complete pAMY- ⁇ 2 vector thereby replacing the codons of the ⁇ -amylase signal sequence with the codons of the avian lysozyme pre-sequence.
- the PCR reaction was performed according to the following program: 1. denaturation: 15 min at 95°C 2. 35 cycles of 30 sec denaturation at 95°C, 1 min annealing at 60°C, and 1 min elongation at 72°C
- reaction mixture was used: pAMY-E2 (1 ng/ ⁇ L), l ⁇ L; primer CL2 hin (100 ⁇ M), 2 ⁇ L; primer CL2 her (100 ⁇ M), 2 ⁇ L; dNTP's (2.5mM each), 8 ⁇ L; H 2 O, 76 ⁇ L; Expand Long Template PCR System (Boeringer; Cat No 1681 834) Buffer 2 (10 x concentrated), 10 ⁇ L; Expand Long Template PCR System Polymerase mixture (lU/ ⁇ L), 0.75 ⁇ L. The resulting PCR product was checked by gel electrophoresis on a 1% agarose gel. Prior to ligation the PCR fragment was modified as follows.
- T4 polymerase resulting in blunt ends with 3'- and 5'-OH-groups.
- 1 ⁇ L T4 polymerase (Boehringer, lU/ ⁇ L) was added to the residual 95 ⁇ L PCR reaction mixture along with 4 ⁇ L dNTP's (2.5 mM each). The sample was incubated for 20 min at 37°c. Subsequently the DNA was precipitated with ethanol and dissolved in 16 ⁇ L deionized water. This was followed by a kinase treatment to add 5 '-phosphates to the blunt-ended PCR product.
- E.coli DH5 ⁇ F' cells were transformed with 10 ⁇ L of the ligation sample.
- Several ampicillin-resistant clones were further characterized via restriction analysis of the isolated plasmid DNA.
- a positive clone was denominated as pUC18-CL-E2-H6 and was used for further modifications as described below.
- a 0.966 kb EcoKl/Bam ⁇ I fragment was isolated from pUC18-CL- ⁇ 2-H6 (harboring CL- E2(384 - 673)-VIEGR-H6) and was ligated into the EcoRI/ ⁇ /nHI-digested pFPMT121 (S ⁇ Q ID NO: 12, Figure 3).
- T4 ligase (Boehringer) was used according to the supplier's conditions. The ligation sample was precipitated with ethanol and dissolved in 10 ⁇ L water. This was used to transform E.coli DH5 ⁇ F' cells, a positive clone was withheld after restriction analysis and the respective plasmid is denominated pFPMT-CL- E2-H6 (SEQ ID NO:32, Figure 14).
- the construction of the shuttle vector was comprised of two steps.
- a first step the pUCl 8-FMD-CL-H6-K-E1-H6 construct was constructed by site-directed mutagenesis.
- the pUC18-FMD-CL-El-H6 was used as template (SEQ ID NO:20; Figure
- the PCR reaction mixture was constituted as follows: pUC18-FMD-CL-El-H6 (2 ng/ ⁇ L),
- the PCR program used consisted of the following steps:
- the sample was applied onto a 1% agarose gel and the correct product band was isolated, by means of the gel extraction kit (Qiagen) according to the supplier's conditions.
- Fifty (50) ng of the purified product has then been self-ligated by use of T4 ligase (Boehringer) according to the supplier's recommendations.
- T4 ligase Tetra-phosphate
- E.coli DH5 ⁇ F' cells were transformed with 5 ⁇ L of the ligation sample.
- the plasmid DNA of several ampicillin-resitant colonies was analyzed by restriction enzyme digestion, a positive clone was withheld and the corresponding plasmid denominated: pUC18-FMD- CL-H6-E1-K-H6 (SEQ ID NO:39, Figure 17).
- the transfer vector was constructed by a two-fragment ligation. In the following construction fragments with Bell cohesive ends were involved. Since i?c/I can cleave its site only on unmethylated DNA, an E. coli dam ' strain was transformed with the involved plasmids pUC18-FMD-CL-H6-K-El-H6 (SEQ ID NO:39, Figure 17) and pFPMT-CL-El (SEQ ID NO:36, Figure 16). From each transformation, an ampicillin- resistant colony was picked, grown in a liquid culture and the unmethylated plasmid DNAs were prepared for the further use.
- the 1.273kb -5c/J/Ht7 ⁇ dIII fragment of the unmethylated plasmid pUC18-FMD-CL- ⁇ 6-K-El- ⁇ 6 (harbouring the FMD promoter, the codons of the CL-H6-K unit, and the start of El) and the 6.057kb BcWHindUl fragment of plasmid pFPMT-CL-El (harbouring the missing part of the El reading frame starting from the Bell site, without C-terminal His tag, as well as the pFPMT121-located elements except for the FMD promoter) were prepared and ligated together for 72 h at 16°C by use of T4 ligase (Boehringer) in a total volume of 20 ⁇ L according to the supplier's specifications.
- T4 ligase Boehringer
- the ligation mixture was placed on a piece of nitrocellulose membrane floating on sterile deionized water in order to desalt the ligation mixture (incubation for 30 min at room temperature).
- E. coli TOP10 cells were transformed by electroporation with 5 ⁇ L of the desalted sample.
- the plasmid DNA of several resulting ampicillin-resistant colonies was analyzed by restriction enzyme digestion.
- a positive clone was withheld and denominated pFPMT-CL-H6-K-El (SEQ ID NO:40, Figure 18).
- H.polymorpha strain RB 11 was been transformed (PEG-mediated DNA uptake protocol essentially as described by (Klebe, R. J. et al. 1983) with the modification of (Roggenkamp, R. et al. 1986) with the different parental shuttle vectors as described in Examples 1 to 5.
- 72 uracil-prototrophic colonies were selected and used for strain generation by the following procedure.
- a 2 mL liquid culture was inoculated and grown in test tubes for 48h (37°C; 160 rpm; angle 45°) in selective medium (YNB/glucose, Difco). This step is defined as the first passaging step.
- a 150 ⁇ L aliquot of the cultures of the first passaging step were used to inoculate 2 L fresh YNB/glucose medium. Again, the cultures have been incubated as described above (second passaging step). Together, eight of such passaging steps were carried out. Aliquots of the cultures after the third and the eighth passaging steps were used to inoculate 2 mL of non-selective YPD medium (Difco). After 48 h of incubation at 37°C (160 rpm; angle 45°; the so-called first stabilization step), 150 ⁇ L aliquots of these YPD cultures have been used to inoculate fresh 2 mL YPD cultures which were incubated as described above (second stabilization step).
- cell pellets were solubilized in sample-buffer (TrisHCl - SDS) and incubated for > 15 minutes at 95°C. Proteins were separated on a 15% polyacryl-amide gel and blotted (wet-blot; bicarbonate buffer) onto nitrocellulose membranes. Blots were developed using a specific murine anti-El (IGH 201) or murine anti-E2 (IGH 216, described by Maertens et al. in WO96/04385) as first antibody, Rabbit- Anti-Mouse- AP was used as second antibody. Staining was performed with NBT-BCIP.
- sample-buffer TrisHCl - SDS
- H. polymorpha a yeast strain closely related to Pichia pasto ⁇ s (Gellissen, G. 2000), is able to express HCV proteins essentially without hyperglycosylation and thus with sugar moieties comparable in size to the HCV envelope proteins expressed by HCV- recombinant vaccinia virus-infected mammalian cells.
- the Hansenula polymorpha strain RBll was deposited on April 19, 2002 under the conditions of the Budapest Treaty at the Mycotheque de PUCL (MUCL), Universite Catholique de Louvain, Laboratoire de mycologie, Place Croix du Sud 3 bte 6, B-1348 Louvain-la-Neuve, Belgium and has the MUCL accession number MUCL43805.
- MUCL Mycotheque de PUCL
- the S. cerevisiae expression plasmid was constructed as follows. An El -coding sequence was isolated as a NsIl/Eco52l fragment from ⁇ G ⁇ MT- ⁇ lsH6 (SEQ ID ⁇ O:6, Figure 1) which was made blunt-ended (using T4 DNA polymerase) and cloned in the pYIG5 vector (SEQ ID NO:41, Figure 19) using T4 DNA ligase (Boehringer) according to the supplier's specifications. The cloning was such that the Els-H6 encoding fragment was joined directly and in frame to the ⁇ MF-coding sequence. The ligation mixture was transformed in E.coli DH5 ⁇ F'cells.
- pYIG5ElH6 plasmid DNA of several ampicilin resistant clones was analyzed by restriction digestion and a positive clone was withheld and denominated as pYIG5ElH6 (ICCG3470; SEQ ID NO:42, Figure 20).
- the expression cassette (containing the ⁇ MF-sequence and the Els-coding region with a His-tag) was transferred as a. BamHl fragment (2790 bp) of pYIG5ElH6 into the BamHl- digested E . colilS. cerevisiae pS Yl shuttle vector (SEQ ID NO:21 , Figure 43).
- the ligation was performed with T4 DNA ligase (Boehringer) according to supplier's conditions.
- the ligation mix was transformed to E .coli DH5 ⁇ F' cells, and the plasmid DNA of several ampicilin resistant colonies was analyzed by restriction enzyme digestion.
- a positive clone was withheld and denominated pSYlaMFElsH6a (ICCG3479; SEQ ID NO:44, Figure 22).
- the S. cerevisiae expression plasmid pSYYIGSE2H6 was constructed as follows. An E2 coding sequence was isolated as a SaUIKp ⁇ l fragment from pBSK-E2sH6 (SEQ ID NO:45, Figure 23) which was made blunt-ended (using T4 DNA polymerase) and subsequently cloned in the pYIG5 vector (SEQ ID NO:41, Figure 19) using T4 DNA ligase (Boehringer) according to the supplier's specifications. The cloning was such that the E2-H6 encoding fragment was joined directly and in frame to the ⁇ MF-coding sequence. The ligation mixture was then transformed to E.
- pYIG5HCCL-22aH6 plasmid DNA of several ampicilin resistant clones was analyzed by restriction digestion and a positive clone withheld and denominated as pYIG5HCCL-22aH6 (ICCG2424; S ⁇ Q ID NO:46, Figure 24).
- the expression cassette (containing the ⁇ MF-sequence and the ⁇ 2 (384 - 673) coding region with a His-tag) was transferred as a BamHl fragment (3281 bp) of pYIG5HCCL- 22aH6 into the BamHl opened E. colilS. cerevisiae pSYl shuttle vector (SEQ ID NO:43, Figure 21).
- the ligation was performed with T4 DNA ligase (Boehringer) according to supplier's conditions.
- the ligation mix was transformed to E. coli DH5 ⁇ F' cells and the plasmid DNA of several ampicilin resistant colonies was analyzed by restriction enzyme digestion. A restriction positive clone was withheld and denominated pSYYIGSE2H6 (ICCG2466; SEQ ID NO:47, Figure 25).
- the S. cerevisiae expression plasmid pSYlYIG7Els was constructed as follows. An El coding sequence was isolated as a NsIl/Eco52l fragment from pGEMT-Els (SEQ ID NO: 6, Figure 1) which was made blunt-ended and cloned into the pYIG7 vector (SEQ ID NO:48, Figure 26) using T4 DNA ligase (Boehringer) according to the supplier's specifications. The cloning was such that the El -encoding fragment was joined directly and in frame to the ⁇ MF-coding sequence. The ligation mixture was transformed to E.
- coli DH5 ⁇ F' cells the plasmid DNA of several ampicilin resistant clones analyzed by restriction digestion and a positive clone withheld and denominated as pYIG7El (SEQ ID NO:49, Figure 27).
- the expression cassette (containing the CL leader sequence and the El (192-326) coding region) was transferred as a BamHl fragment (2790 bp) of pYIG7El into the BamHl- digested E. colilS. cerevisiae pSYl shuttle vector (SEQ ID NO:43, Figure 21).
- the ligation was performed with T4 DNA ligase (Boehringer) according to supplier's conditions.
- the ligation mix was transformed to E.
- Said glycosylation-deficient strain IYCC155 was transformed with the plasmids as described in Examples 7 to 9 essentially by to the lithium acetate method as described by Elble (Elble, R. 1992).
- Several Ura complemented strains were picked from a selective YNB + 2 % agar plate (Difco) and used to inoculate 2ml YNB+2%glucose. These cultures were incubated for 72 h, 37°C, 200 rpm on orbital shaker, and the culture supernatant and intracellular fractions were analysed for expression of El by western blot developed with a El specific murine monoclonal antibody (IGH 201). A high producing clone was withheld for further experiments.
- IGH 201 El specific murine monoclonal antibody
- the shuttle vector pPICZalphaE'ElsH6 was constructed starting from the pPICZalphaA vector (Invitrogen; SEQ ID NO:51, Figure 29). In a first step said vector was adapted in order to enable cloning of the El coding sequence directly behind the cleavage site of the KEX2 or STE13 processing proteases, respectively. Therefore pPICZalphaA was digested with Xliol and Notl. The digest was separated on a 1% agarose gel and the 3519 kb fragment (major part of vector) was isolated and purified by means of a gel extraction kit (Qiagen).
- linker oligonucleotide 5'-TCGAGAAAAGAGAGGCTGAAGCCTGCAGCATATGC-3' (SEQ ID NO: 56) 8650: 5'-GGCCGCATATGCTGCAGGCTTCAGCCTCTCTTTTC-3' (SEQ ID NO:57) which yield, after annealing, the linker oligonucleotide:
- shuttle vectors pPICZalphaD' and pPICZalphaE' have newly introduced cloning sites directly behind the cleavage site of the respective processing proteases, KEX2 and STE13.
- the E1-H6 coding sequence was isolated as a NsIllEco52l fragment from pGEMT-ElsH6 (SEQ ID NO:6, Figure 1).
- the fragment was purified using a gel extraction kit (Qiagen) after separation of the digest on a 1% agarose gel.
- the resulting fragment was made blunt- ended (using T4 DNA polymerase) and ligated into either pPICZalphaD' or pPICZalphaE' directly behind the respective processing protease cleavage site.
- the ligation mixtures were transformed to E. coli TOPI OF' cells and plasmid DNA of several zeocin resistant colonies analyzed by restriction enzyme digestion. Positive clones were withheld and denominated pPICZalphaD 'ElsH6 (ICCG3694; SEQ ID NO:58, Figure 32) and pPICZalphaE'El sH6 (ICCG3475; SEQ ID NO:59, Figure 33), respectively.
- the shuttle vectors pPICZalphaD' and pPICZalphaE' were constructed as described in Example 11.
- the E2-H6 coding sequence was isolated as a SatllKpnl fragment from pBSK-E2sH6 (SEQ ID NO:45, Figure 23).
- the fragment was purified with a gel extraction kit (Qiagen) after separation of the digest on a 1% agarose gel.
- the resulting fragment was made blunt- ended (using T4 DNA polymerase) and ligated into either pPICZalphaD' or pPICZalphaE' directly behind the respective processing protease cleavage site.
- the ligation mixture was transformed to E. coli TOPI OF' cellls and the plasmid DNA of several zeocin resistant colonies was analyzed by restriction enzyme digestion. Positive clone were withheld and denominated pPICZalphaD 'E2sH6 (ICCG3692; SEQ ID NO:60, Figure 34) and pPICZalphaE'E2sH6 (ICGG3476; SEQ ID NO:61, Figure 35), respectively.
- the P. pastoris shuttle plasmids as described in Examples 11 and 12 were transformed to P. pastoris cells according to the supplier's conditions (Invitrogen). An El- and an E2- producing strain were withheld for further characterization.
- the HCV envelope proteins were expressed in P. pastoris, a yeast strain well known for the fact that hyperglycosylation is normally absent (Gellissen, G. 2000) and previously used to express dengue virus E protein as GST fusion (Sugrue, R. J. et al. 1997).
- the resulting P. pastoris-exp ⁇ essed HCV envelope proteins displayed a comparable glycosylation as is observed in wild-type Saccharomyces strains. More specifically, the HCV envelope proteins produced by P. pastoris are hyperglycosylated (based on the molecular weight of the expression products detected in western-blots of proteins isolated from transformed P. pastoris cells).
- a master cell bank and working cell bank were prepared.
- Cryo-vials were prepared from a mid-exponentially grown shake flask culture (incubation conditions as for fermentation seed cultures, see below). Glycerol was added (50 % final cone.) as a cryoprotectant.
- Seed cultures were started from a cryo-preserved working cell bank vial and grown in 500 mL medium (YNB supplemented with 2 % sucrose, Difco) in a 2 L Erlenmeyer shake flasks at 37°C, 200 rpm for 48h. Fermentations were typically performed in Biostat C fermentors with a working volume of 15 L (B.Braun Int., Melsungen, Germany).
- the fermentation medium contained 1% Yeast Extract, 2% Peptone and 2 % sucrose as carbon source.
- Poly-ethylene glycol was used as anti-foam agent.
- Temperature, pH and dissolved oxygen were typically controlled during the fermentation, applicable set-points are summarised in Table 1. Dissolved oxygen was cascade controlled by agitation/aeration. pH was controlled by addition of NaOH (0.5 M) or H 3 PO solution (8.5 %).
- the fermentation was started by the addition of 10 % seed-culture. During the growth phase the sucrose concentration was monitored off-line by HPLC analysis (Polysphere Column OAKC Merck).
- the dissolved oxygen was controlled by cascade control (agitation/aeration). After complete metabolisation of sucrose the heterologous protein production was driven by the endogenous produced ethanol supplemented with stepwise addition of EtOH in order to maintain the concentration at approximately 0.5 % (off-line HPLC analysis, polyspher OAKC column) During this induction phase the dissolved oxygen was controlled below 5% air-saturation, by manual adjustment of airflow rate and agitator speed.
- a master cell bank and working cell bank were prepared.
- Cryo-vials were prepared from a mid-exponentially grown shake flask culture (incubation conditions as for fermentation seed cultures, see below). Glycerol was added (50 % final cone.) as a cryoprotectant.
- Fermentation Seed cultures were started from a cryo-preserved (-70°C) working cell bank vial and grown in 500 mL medium (YPD, Difco) in a 2 L Erlenmeyer shake flasks at 37°C, 200 rpm for 48h.
- the fermentation medium contained 1% Yeast Extract, 2% Peptone and 1% glycerol as carbon source. Poly-ethylene glycol was used as anti-foam agent.
- the fermentation was started by the addition of 10 % seed-culture. During the growth phase the glycerol concentration was monitored off-line (Polysphere Column OAKC Merck) and 24 h after complete glycerol consumption 1% methanol was added in order to induce the heterologous protein expression. The fermentation was harvested 24 h post induction by concentration via tangential flow filtration followed by centrifugation of the concentrated cell suspension to obtain cell pellets. If not analyzed immediately, cell pellets were stored at -70°C.
- the small scale production was typically performed at 500 mL scale in 2 L shake flasks and were started with a 10 % inoculation in expression medium, containing 1% Yeast extract, 2 % Peptone (both Difco), and 2 % glycerol as carbon source. Incubation conditions were as for the seed culture. Induction was started by addition of 1 % MeOH approximately 72 h after inoculation. The cells were collected 24 h post induction by centrifugation. If not analyzed immediately, cell pellets were stored at -70°C.
- HCV Els genotype lb HCV Els (aa 192-326) and HCV E2s (aa 383-673 extended by the VIEGR (SEQ ID NO:69)-sequence) were expressed as C-terminal his-tagged (H6, HHHHHH, SEQ ID NO: 63; said HCV proteins are furtheron in this Example denoted as ⁇ MF-El-H6 and ⁇ MF ⁇ E2-H6) proteins
- a rapid and efficient purification of the expressed products after guanidinium chloride (GuHCl)-solubilization of the yeast cells was performed on Ni-IDA (Ni-iminodiacetic acid).
- cell pellets were resuspended in 50 mM phosphate, 6M GuHCl, pH 7.4 (9 vol/g cells). Proteins were sulfonated overnight at room temperature (RT) in the presence of 320 mM (4% w/v) sodium sulfite and 65 mM (2% w/v) sodium tetrathionate. The lysate was cleared after a freeze-thaw cycle by centrifugation (10.000 g, 30 min, 4°C) and Empigen (Albright &Wilson, UK) and imidazole were added to the supernatant to final concentrations of 1% (w/v) and 20 mM, respectively.
- the sample was filtrated (0.22 ⁇ M) and loaded on a Ni-IDA Sepharose FF column, which was equilibrated with 50 mM phosphate, 6M GuHCl, 1% Empigen (buffer A) supplemented with 20 mM imidazole.
- the column was washed sequentially with buffer A containing 20 mM and 50 mM imidazole, respectively, till absorbance at 280 nm reached baseline level.
- the his- tagged products were eluted by applying buffer D, 50 mM phosphate, 6M GuHCl, 0.2 % (for El) or 1 % (for E2) Empigen, 200 mM imidazole.
- the eluted materials were analyzed by SDS-PAGE and western-blot using a specific monoclonal antibodies directed against El (IGH201), orE2 (IGH212).
- the degradation products may be a result of a Kex-2 like cleavage (e.g. the cleavage observed after aa 196 of El which is a cleavage after an arginine), which is also required for the cleavage of the ⁇ -mating factor leader and which can thus not be blocked without disturbing this essential process.
- a Kex-2 like cleavage e.g. the cleavage observed after aa 196 of El which is a cleavage after an arginine
- a high El producing clone derived from transformation of S. cerevisiae IYCC155 with pSYlYIG7Els (SEQ ID NO:50; Figure 28) was compared with a high producing clone derived from transformation of S. cerevisiae IYCC155 with pSYlaMFElsH ⁇ aYIGlEls (SEQ ID NO:44; Figure 22).
- the intracellular expression of the El protein was evaluated after 2 up to 7 days after induction, and this by means of Western-blot using the El specific monoclonal antibody (IGH 201). As can be judged from Figure 40, maximal expression was observed after 2 days for both strains but the expression patterns for both strains are completely different.
- the hybridoma cell line producting the monoclonal antibody directed against El (IGH201) was deposited on March 12, 1998 under the conditions of the Budapest Treaty at the European Collection of Cell Cultures, Centre for Applied Microbiology & Research, Salisbury, Wiltshire SP4 OJG, UK, and has the accession number ECACC 98031216).
- the monoclonal antibody directed against E2 (IGH212) has been described as antibody 12D11F2 in Example 7.4 by Maertens et al. in WO96/04385.
- leader sequences were used to replace the S. cerevisiae ⁇ MF leader peptide including CHH (leader sequence of Carcinus rnaenas hyperglycemic hormone), Amyl (leader sequence of amylase from S. occidentalis), Gaml (leader sequence of glucoamylase from S. occidentalis), Phy5 (leader sequence from fungal phytase), phol (leader sequence from acid phosphatase from Pichia pastoris) and CL (leader of avian lysozyme C, 1,4-beta-N-acetylmuramidase C) and linked to E1-H6 (i.e. El with C-terminal his-tag).
- CHH leader sequence of Carcinus rnaenas hyperglycemic hormone
- Amyl leader sequence of amylase from S. occidentalis
- Gaml leader sequence of glucoamylase from S. occidentalis
- Phy5 leader sequence from fungal phytase
- phol leader sequence
- the higher hydrophobic character of the non-glycosylated material may be used to select and optimize other enrichment procedures.
- the correct removal of the CL leader peptide from the CL-E1- ⁇ 6 protein was further confirmed by mass spectrometry which also confirmed that up to 4 out of the 5 N-glycosylation sites of genotype lb Els can be occupied, whereby the sequence NNSS (amino acids 233 to 236; SEQ ID NO:73) are considered to be a single N-glycosylation site.
- CL-E2-H6 The efficiency of removal of the CL leader peptide from CL-E2-VIEGR-H6 (furtheron in this Example denoted as "CL-E2-H6") protein expressed in Hansenula polymorpha was analyzed. Since the HCV E2s (aa 383-673) was expressed as a his-tagged protein, a rapid and efficient purification of the expressed protein after GuHCl-solubilization of collected cells was performed on Ni-IDA. In brief, cell pellets were resuspended in 30 mM phosphate, 6 M GuHCl, pH 7.2 (9 mL buffer/g cells).
- the protein was sulfonated overnight at room temperature in the presence of 320 mM (4% w/v) sodium sulfite and 65 mM (2% w/v) sodium tetrathionate.
- the lysate was cleared after a freeze-thaw cycle by centrifugation (10.000 g, 30 min, 4°C).
- Empigen BB Albright & Wilson
- imidazole were added to a final concentration of 1% (w/v) and 20 mM, respectively. All further chromatographic steps were executed on an Akta FPLC workstation (Pharmacia).
- the sample was filtrated through a 0.22 ⁇ m pore size membrane (cellulose acetate) and loaded on a Ni-IDA column (Chelating Sepharose FF loaded with Ni 2+ , Pharmacia), which was equilibrated with 50 mM phosphate, 6 M GuHCl, 1 % Empigen BB, pH 7.2 (buffer A) supplemented with 20 mM imidazole.
- the column was washed sequentially with buffer A containing 20 mM and 50 mM imidazole, respectively, till the absorbance at 280 nm reached the baseline level.
- the his-tagged products were eluted by applying buffer D, 50 mM phosphate, 6 M GuHCl, 0.2 % Empigen BB (pH 7.2), 200 mM imidazole.
- the purified materials were analysed by SDS-PAGE and western-blot using a specific monoclonal antibody directed against E2 (IGH212) ( Figure 41).
- the IMAC-purified E2- H6 protein was also subjected to N-terminal sequencing by Edman degradation. Thereto proteins were treated with N-glycosidase F (Roche) (0.2 U/ ⁇ g E2, 1 h incubation at 37°C in PBS/3%) empigen BB) or left untreated.
- the glycosylated and deglycosylated E2-H6 proteins were subjected to SDS-PAGE and blotted on a PNDF-membrane for amino acid sequencing (analysis was performed on a PROCISETM 492 protein sequencer, Applied Biosystems). Since at this stage, SDS-PAGE revealed some degradation products, a further fractionation by size exclusion chromatography was performed.
- the Ni-IDA eluate was concentrated by ultrafiltration (MWCO 10 kDa, centriplus, Amicon, Millipore) and loaded on a Superdex G200 (Pharmacia) in PBS, 1% Empigen BB.
- Elution fractions containing mainly intact E2s related products with a Mr between -30 kDa and ⁇ 70 kDa based on the migration on SDS-PAGE, were pooled and eventually alkylated (incubation with 5 mM DTT for 30 minutes at 37°C, followed by incubation with 20 mM iodoacetamide for 30 minutes at 37°C).
- the possible presence of degradation products after IMAC purification can thus be overcome by a further fractionation of the intact product by means of size exclusion chromatography. An unexpectedly good result was obtained. Based on the N-terminal sequencing the amount of E2 product from which the CL leader peptide is removed could be estimated.
- the total amount of protein products is calculated as pmol of protein based on the intensity of the peaks recovered by Edman degradation. Subsequently, for each specific protein (i.e. for each 'detected N-terminus') the mol % versus the total is estimated. In the current experiment, only the correct N- terminus of E2-H6 was detected and other variants of E2-H6 lacking amino acid of the E2 protein or containing N-terminal amino acids not comprised in the E2 protein were absent. In conclusion, the E2-H6 protein expressed by H. polymorpha as CL-E2-H6 protein was isolated without any further in vitro processing as a > 95 % correctly cleaved protein. This is in sharp contrast with the fidelity of leader peptide removal by H. polymorpha of the ⁇ MF-E2-H6 protein to the E2-H6 protein, which was estimated to occur in 25 % of the isolated proteins (see Table 3).
- Endoproteinase Lys-C digested protein sample was applied on a Ni-IDA column after a 10-fold dilution with 10 mM NaH 2 PO 4 .3H 2 O, 1 % (v/v) Empigen B, pH 7.2 (buffer B) followed by washing with buffer B till the absorbance at 280 nm reached the baseline level.
- the flow through was collected in different fractions (1-40) that were screened for the presence of Els-products (Figure 44).
- the fractions (7-28), containing intact El from which the N-terminal H6-K (and possibly residual CL-H6-K) tail is removed (with a Mr between ⁇ 15 kDa and ⁇ 30 kDa based on the migration on SDS-PAGE followed by silver staining or western blot analysis using a specific monoclonal antibody directed against El (IGH201), were pooled and alkylated (incubation with 5 mM DTT for 30 minutes at 37°C, followed by incubation with 20 mM iodoacetamide for 30 minutes at 37°C). This material was subjected to N-terminal sequencing (Edman degradation).
- HCV envelope proteins In order to find specific purification steps for HCV envelope proteins from yeast cells binding with heparin was evaluated. Heparin is known to bind to several viruses and consequently binding to the HCV envelope has already been suggested (Garson, J. A. et al. 1999). In order to analyze this potential binding, heparin was biotinylated and interaction with HCV El analyzed in microtiterplates coated with either sulfonated HCV El from H. polymorpha, alkylated HCV El from H polymorpha (both produced as described in Example 16) and alkylated HCV El from a culture of mammalian cells transfected with a vaccinia expression vector.
- VLPs VIRUS-LIKE PARTICLES
- H. polymorpha Conversion of the HCV El and E2 envelope proteins expressed in H. polymorpha (Examples 16 to 18) to VLPs was done essentially as described by Depla et al. in WO99/67285 and by Bosman et al. in WO01/30815. Briefly, after cultivation of the transformed H. polymorpha cells during which the HCV envelope proteins were expressed, cells were harvested, lysed in GuHCl and sulphonated as described in Example 17. His- tagged proteins were subsequently purified by IMAC and concentrated by ultrafiltration as described in Example 17. VLP-formation of HCV envelope proteins with sulphonated Cys-thiol groups
- the concentrated HCV envelope proteins sulphonated during the isolation procedure were not subjected to a reducing treatment and loaded on a size-exclusion chromatograpy column (Superdex G200, Pharmacia) equilibrated with PBS, 1 % (v/v) Empigen.
- the eluted fractions were analyzed by SDS-PAGE and western blotting.
- the fractions with a relative Mr ⁇ 29 — 15 kD (based on SDS-PAGE migration) were pooled, concentrated and loaded on Superdex G200, equilibrated with PBS, 3%> (w/v) betain, to enforce virus like particle formation (VLP).
- the fractions were pooled, concentrated and desalted to PBS, 0.5% (w/v) betain.
- the concentrated HCV envelope proteins sulphonated during the isolation procedure were subjected to a reducing treatment (incubation in the presence of 5 mM DTT in PBS) to convert the sulphonated Cys-thiol groups to free Cys-thiol groups.
- Irreversible Cys-thiol modification was performed by (i) incubation for 30 min in the presence of 20 mM iodoacetamide, or by (ii) incubation for 30 min in the presence of 5 mM N-ethylmaleimide (NEM) and 15 mM biotin-N-ethylmaleimide.
- the proteins were subsequently loaded on a size-exclusion chromatograpy column (Superdex G200, Pharmacia) equilibrated with PBS, 1 % (v/v) Empigen in case of iodoacetamide-blocking, or with PBS, 0.2 % CHAPS in case of blocking with NEM and biotin-NEM.
- the eluted fractions were analyzed by SDS- PAGE and Western blotting.
- the fractions with a relative Mr -29—15 kD were pooled, concentrated and, to force virus-like particle formation, loaded on a Superdex G200 column equilibrated with PBS, 3% (w/v) betain.
- fractions were pooled, concentrated and desalted to PBS, 0.5% (w/v) betain in case of iodoacetamide-blocking, or with PBS, 0.05 %> CHAPS in case of blocking with NEM and biotin-NEM.
- the concentrated HCV envelope proteins sulphonated during the isolation procedure were subjected to a reducing treatment (incubation in the presence of 5 mM DTT in PBS) to convert the sulphonated Cys-thiol groups to free Cys-thiol groups.
- Reversible Cys-thiol modification was performed by incubation for 30 min in the presence of dithiodipyridine (DTDP), dithiocarbamate (DTC) or cysteine.
- DTDP dithiodipyridine
- DTC dithiocarbamate
- cysteine cysteine.
- the proteins were subsequently loaded on a size-exclusion chromatograpy column (Superdex G200, Pharmacia) equilibrated with PBS, 1 % (v/v) Empigen. The eluted fractions were analyzed by SDS-PAGE and Western blotting.
- the fractions with a relative Mr -29—15 kD were pooled, concentrated and loaded on Superdex G200, equilibrated with PBS, 3% (w/v) betain, to enforce virus like particle formation (VLP).
- the fractions were pooled, concentrated and desalted to PBS, 0.5%> (w/v) betain.
- VLP particle size was determined by Dynamic Light Scattering.
- a particle-size analyzer (Model Zetasizer 1000 ⁇ S, Malvern Instruments Ltd., Malvern, Worcester UK) was used which was controlled by photon correlation spectroscopy (PCS) software.
- Photon correlation spectroscopy or dynamic light scattering (DLS) is an optical method that measures brownian motion and relates this to the size of particles.
- Light from a continuous, visible laser beam is directed through an ensemble of macromolecules or particles in suspension and moving under brownian motion. Some of the laser light is scattered by the particles and this scattered light is measured by a photomultiplier. Fluctuations in the intensity of scattered light are converted into electrical pulses which are fed into a correlator. This generates the autocorrelation function which is passed to a computer where the appropriate data analysis is performed.
- the laser used was a 10 mW monochromatic coherent He-Ne laser with a fixed wavelength of 633 nm. For each sample, three to six consecutive measurements were taken.
- HCV El The reactivity of Hansenula-Oroduced HCV E1-H6 with sera from HCV chronic carriers was compared to the reactivity of HCV El produced by HCV-recombinant vaccinia virus- infected mammalian cells as described by Depla et al. in WO 99/67285. Both HCV-E1 preparations tested consisted of VLP' s wherein the HCV El proteins were alkylated with NEM and biotin-NEM. The reactivities of both HCV El VLP -preparations with sera from HCV chronic carriers was determined by ELISA. The results are summarized in Table 6. As can be derived from Table 6, no differences in reactivity were noted between HCV El expressed in HCV-recombinant vaccinia virus-infected mammalian cells and HCV El expressed in H polymorpha.
- HCV-E1 preparations tested consisted of VLP's wherein the HCV El proteins were alkylated with iodoacetamide. Both VLP preparations were fo ⁇ nulated with alum and injected in Balb/c mice (3 intramuscular/subcutaneous injections with a three week interval between each and each consisting of 5 ⁇ g El in 125 ⁇ l containing 0.13% Alhydrogel, Superfos, Denmark). Mice were bled ten days after the third immunization.
- Antibody titers were determined by ELISA (see Example 21) wherein either El produced in mammalian cells ("M”) or ⁇ ansenula- produced El (“ ⁇ ”) were coated directly on the ELISA solid support whereafter the ELISA plates were blocked with casein.
- the antibody titers determined were end point titers.
- the end point titer is determined as the dilution of serum resulting in an OD (as determined by ELISA) equal to two times the mean of the background of the assay.
- Figure 51 shows that no significant differences were observed between the immunogenic properties of both El -compositions and that the determined antibody titers are independent of the antigen used in the ELISA to perform the end point titration.
- yeast-derived ⁇ CV El induced upon vaccination a protective response similar to the protective response obtained upon vaccination with alkylated ⁇ CV El derived from mammalian cell culture. The latter response was able to prevent chronic evolution of ⁇ CV after an acute infection.
- HCV E1-H6 The reactivity of Hansenula-prodaced HCV E1-H6 with sera from HCV chronic carriers was compared to the reactivity of HCV El produced by HCV-recombinant vaccinia virus- infected mammalian cells as described by Depla et al. in WO99/67285. Both HCV-E1 preparations tested consisted of VLP's wherein the Hansenula-prodaced HCV El proteins were sulphonated and the HCV El produced by mammalian cells was alkylated. The results are given in Table 7. Although the overall (average) reactivity was identical, some major differences were noted for individual sera.
- HCV-E1 preparations tested consisted of VLP's. Both VLP preparations were formulated with alum and injected in Balb/c mice (3 intramuscular/subcutaneous injections with a three week interval between each and each consisting of 5 ⁇ g El in 125 ⁇ l containing 0.13% Alhydrogel, Superfos, Denmark).
- HCV El wherein the cysteine thiol-gorups are modified in a reversible way may be more immunogenic and thus have an increased potency as a vaccine protecting against HCV (chronic infection).
- induction of a response to neo- epitopes induced by irrreversible blocking is less likely to occur.
- Table 7 Antigenicity of alkylated El (produced in mammalian cell culture) or sulphonated E1-H6 (produced in H. polymorpha) was evaluated on a panel of sera from human HCV chronic carriers ("patient sera") and a panel of control sera ("blood donor sera”). To this purpose El was bound to ELISA plates, after which the plates were further saturated with casein.
- the results obtained in this experiment are clearly different from the findings of Mustilli and coworkers (Mustilli, A. C. et al. 1999) who expressed the HCV E2 protein both in Saccharomyces cerevisiae and Kluyveromyces lactis.
- the purified yeast-produced E2 was, however, different from the HCV E2 produced by mammalian (CHO) cells in that a lower reactivity was observed with sera from chimpanzees immunized with HCV E2 produced by mammalian cells while reactivity with monoclonal antibodies was higher for the yeast- produced HCV E2.
- the glycosylation profiles were compared of Hansenula-p ⁇ odaced HCV El and HCV El produced by HCV-recombinant vaccinia virus-infected mammalian cells as described by Depla et al. in WO99/67285. This was done by means of fluorophore-assisted carbohydrate electrophoresis (FACE). Thereto, oligosaccharides were released from Els produced by mammalian cells or Hansenula by peptide-N-glycosidase (PNGase F) and labelled with ANTS (the El proteins were alkylated with iodoacetamide prior to PNGase F digestion).
- FACE fluorophore-assisted carbohydrate electrophoresis
- ANTS-labeled oligosaccharides were separated by PAGE on a 21% polyacrylamide gel at a current of 15 rnA at 4°C for 2-3 h. From Figure 54, it was concluded that the oligosaccharides on El produced by mammalian cells and E1-H6 produced by Hansenula migrate like oligomaltose with a degree of polymerization between 7 and 11 monosaccharides. This indicates that the Hansenula expression system surprisingly leads to an El protein which is not hyperglycosylated and which has sugar chains with a length similar to the sugar chains added to El proteins produced in mammalian cells.
- Example 26 expression of HCV envelope proteins in yeast.
- the promotor/gene/terminator-expression cassette was transferred as a BamHl cassette to the BamHl opened E.colil S.cerevisiae shuttlevector pSYl, resulting in vector ICCG No. 3479 (Fig 22).
- This shuttlevector was then transformed to the S.cerevisiae strain IYCC No. 155 which is a glycosylation deficient strain.
- the promotor/gene/terminator-expression cassette was transferred as a BamHl cassette to the BamHl opened E.colil S.cerevisiae shuttlevector pSYl, resulting in vector ICCG No. 2466 (Fig. 25).
- This shuttle vector was then transformed to the S.cerevisiae strain IYCC No. 155 which is a glycosylation deficient strain.
- H.pofymorpha For the construction of an expression vector for HCV El in H.pofymorpha, a DNA coding for HCV Els (aa 192-326) ORF was exactly fused to the S.cerevisiae ⁇ -mating factor preprosequence in vector pFPMT-El-11 (see Gellissen et al., 1992 for description of parent vector; see Figure 5 for pFPMT-El-11). This vector was subsequently transformed into H.pofymorpha strain RBl l and was, after selection for genomic integration and expression analysis, stored under IYCC No. 205.
- H.pofymorpha For the construction of an expression vector for HCV E2 in H.pofymorpha, a DNA coding for HCV E2s (aa384-673) ORF was exactly fused to the S.cerevisiae ⁇ -mating factor preprosequence in vector pFPMT-E2 (see Gellissen et al., 1992 for description of parent vector). This vector was subsequently transformed into H.pofymorpha strain RBl l and was, after selection for genomic integration and expression analysis, stored under IYCC No. 168.
- Seed cultures of the recombinant Saccharomyces cerevisiae strains were grown in YNB (Difco) supplemented with 2% sucrose as carbon source. These seed cultures were started from a cryo-preserved working cell bank vial and grown in 500 ml medium in a 2 1 Erlenmeyer shake flasks at 37°C, 200 rpm for 48h. Fermentations were performed in Biostat C fermentors (B.Braun Int., Melsoder, Germany). The medium contained 1%> Yeast Extract, 2% Peptone and 2% sucrose as carbon source; Poly-ethylene glycol was used as anti-foam agent.
- Recombinant Hansenula polymorpha seed cultures were grown in rich YPD medium (Difco). These seed cultures were started from a cryo-preserved working cell bank vial and grown in 500 ml medium in a 2 1 Erlenmeyer shake flasks at 37°C, 200 rpm for 48h. Fermentations were performed in Biostat C fermentors (B.Braun Int., Melsungen, Germany). The medium contained 1%> Yeast Extract, 2% Peptone and 1% glycerol as carbon source; Poly-ethylene glycol was used as anti-foam agent. Temperature was controlled at 37°C, pH at 4.8 and aeration was kept constant at 1.5 wm.
- Dissolved oxygen concentration was maintained above 30% air saturation by changing the agitator speed throughout the fermentation.
- the fermentation was started by the addition of 10% seed- culture.
- the glycerol concentration was monitored off-line and 24 h after complete glycerol consumption 1% methanol was added in order to induce the heterologous protein expression.
- Cells were collected after 24h of induction by tangential flow filtration followed by a centrifugation step. Cell pellets were stored at-70°C.
- HCV envelope proteins comparable to what is observed in wild type Saccharomyces strains, i.e. carrying hyperglycosylation, and this based on the molecular weight of the expression products detected in western-blots of cell lysates.
- Hansenula polymorpha a yeast strain closely related to Pichia pastoris (Gelissen 2000), is able to express HCV proteins essentially without hyperglycosylation and thus with a sugar moiety comparable in size to what mammalian cells express.
- Hansenula polymorpha a yeast strain closely related to Pichia pastoris (Gelissen 2000)
- Hansenula polymorpha a yeast strain closely related to Pichia pastoris (Gelissen 2000)
- Hansenula polymorpha was found to be able to produce an HCV envelope protein which is not hyperglycosylated.
- Example 27 Biochemical properties of HCV El and E2 proteins expressed in selected yeast strains under the ⁇ -mating factor leader sequence.
- the expression products of HCV El and E2 protein constructs with the ⁇ -mating factor leader sequence of Saccharomyces cerevisiae in Hansenula polymorpha or Saccharomyces cerevisiae glycosylation minus strain were further analyzed. Since both HCV Els (aa 192- 326) and HCV E2s (aa 383-673) were expressed as C-terminal (his) 6 -tagged proteins a rapid and efficient purification of the expressed and GuHCl-solubilized products was performed on Ni-IDA.
- cell pellets were resuspended in 50 mM phosphate, 6M Gu.HCl, pH 7.4 (9vol/g cells). Proteins were sulfonated overnight at room temperature (RT) in the presence of 320 mM (4% w/v) sodium sulfite and 65 mM (2% w/v) sodium tetrathionate. The lysate was cleared after a freeze-thaw cycle by centrifugation (10.000 g, 30 min, 4°C) and Empigen (Albright & Wilson, UK) and imidazole were added to the supernatant to a final concentration of 1% (w/v) and 20 mM respectively.
- the sample was filtrated and loaded on a Ni-IDA Sepharose FF column, which was equilibrated with 50 mM phosphate, 6M Gu.HCl, 1% Empigen (buffer A) supplemented with 20 mM Imidazole.
- the column was washed sequentially with buffer A containing 20 mM and 50 mM Imidazole respectively till absorbance at 280 nm reached baseline level.
- the his- tagged products were eluted by applying buffer A, 200 mM Imidazole or 50 mM phosphate, 6M Gu.HCl, 0.2% (for El) or 1% (for E2) Empigen, 200 mM Imidazole.
- the purified materials were analyzed by SDS-PAGE and western-blot using a specific monoclonal antibodies directed against El (IGH201, deposited under accession nr 98031216 at ECACC), or E2 (IGH 212).
- El-products were immediately analyzed by Edman degradation.
- CHH leader sequence of Carcinus maenas hyperglycemic hormone
- Amyl leader sequence of amylase from Saccharomyces occidentalis
- Gaml leader sequence of glucoamylase from Saccharomyces occidentalis
- Phy 5 leader sequence from fungal phytase
- phol leader sequence from acid phosphatase from Pichia pastoris
- CL lysozyme C, 1,4-beta-N- acetylmuramidase C) and linked to Els with C-terminal (his) 6 tag.
- the HCV El produced in Hansenula polymorpha with the CL leader was purified on Ni- IDA and finally eluted in 0.2%o (w/v) Empigen BB as described in Example 27. The Empigen was exchanged for 3% betain on size exclusion chromatography. Finally, the HCV El was desalted to PBS with 0.5% betain. In brief, the 200 mM imidazole peak was concentrated by ultrafiltration (lOkD MWCO, Centriplus, Amicon, Millipore) and the his- tagged Els was desulfonated by treatment with 5 mM DTT and the thiol groups were alkylated after 30 min with iodoacetamide (20 mM).
- the alkylated product was loaded on Superdex G200 (Pharmacia), which was equilibrated with PBS, 1% Empigen. Elution fractions were analyzed by SDS-PAGE and Western blotting. The fractions with a relative Mr -29—18 kD (based on SDS-PAGE migration) were pooled, concentrated and loaded on Superdex G200, equilibrated with PBS, 3% (w/v) betain, to enforce virus like particle formation (VLP). The fractions were pooled, concentrated and desalted to PBS, 0.5% (w/v) betain.
- Biotinylated his-tagged Els was obtained by alkylation with 5mM N-ethylmaleimide (NEM)/ 15 mM NEM.bio after reduction with DTT.
- NEM N-ethylmaleimide
- the gelfiltration chromatographies (SEC) in the presence Empigen, the VLP formation step and desalting step were performed as described for acetamidated Els, except that the 3% and 0.5% betain in the buffer was replaced by 0.2 (w/v) and 0.05% (w/v) CHAPS respectively.
- the yeast derived protein forms particles with a size between 25 and 45 nm as determined by Dynamic Light Scattering.
- a particle-size analyzer Model Zetasizer 1000 HS, Malvern Instruments Ltd., Malvern, Worcester UK
- Photon correlation spectroscopy or dynamic light scattering is an optical method that measures brownian motion and relates this to the size of particles. Light from a continuous, visible laser beam is directed through an ensemble of macromolecules or particles in suspension and moving under brownian motion.
- Some of the laser light is scattered by the particles and this scattered light is measured by a photomultiplier. Fluctuations in the intensity of scattered light are converted into electrical pulses which are fed into a correlator. This generates the autocorrelation function which is passed to a computer where the appropriate data analysis is performed.
- the laser used was a 10 mW monochromatic coherent He-Ne laser with a fixed wavelength of 633 nm. For each sample, six consecutive measurements were taken. The reactivity of this HCV El with sera from HCV chronic carriers was determined in ELISA and compared to the reactivity with HCV El from mammalian cell culture which was prepared as described in WO 99/67285. As can be judged from Table 6 no differences were noted between HCV El expressed in mammalian cells and HCV El expressed in Hansenula polymorpha.
- HCV El from Hansenula expressed with the CL leader and alkylated with iodo-acetamide or HCV El derived from mammalian cell culture similarly alkylated as described in PCT/EP99/04342 was formulated with alum and injected in Balb/c mice (3 intramuscular/subcutaneous injections with a three week interval and consisting of 5 ⁇ g El in 125 ⁇ l containing 0.13% Alhydrogel, Superfos, Denmark). Mice were bled ten days after the third immunization. The end point titers of the induced antibodies were determined for each series of mice both on mammalian and Hansenula derived El. Figure 51 shows that no differences were observed and that the obtained titers are also independent of the antigen used in ELISA to perform titration.
- the yeast derived HCV El induced a similar protective response upon vaccination.
- Example 31 production of reversible cysteine blocked HCV El: antigenic and immunogenic profile
- Example 30 the immunogenicity of alkylated HCV El from yeast and mammalian cell culture was compared. Alkylation is, however, an irreversible modification. Therefore, we also tried reversible modifications of the cysteines by dithiodipyridine (DTDP), dithiocarbamate (DTC), cysteine and sulfonation.
- DTDP dithiodipyridine
- DTC dithiocarbamate
- cysteine and sulfonation H. polymorpha cell pellets homogenization, cell lysis, protein sulfonation and chromatography on IDA-Sepharose were performed for his-tagged HCV Els as described in Example 27. The sulfonated product was loaded without any reduction treatment on SEC in the presence of 1% Empigen, and VLP formation was forced by SEC in 3%> (w/v) betain.
- the eluate was concentrated and desalted to 0.5% betain.
- sulfonated HCV Els was treated with 5mM DTT in PBS and DTDP, DTC or cysteine were added after 30 min at RT till a final concentration of 20 mM.
- the SEC in 1%> Empigen, the VLP formation step on SEC in 3% betain and the desalting step were performed as described for the acetamide modified his-tagged HCV Els in Example 4.
- the HCV Els.his containing fractions were stored at -70°C after addition of the respective reversible blocking agent (2 mM final concentration) in order to prevent disulfide exchanges and aggregation.
- HCV El sulfonated HCV El derived from Hansenula polymorpha
- HCV El which contains 8 cysteines
- the other reversible cysteine modifying agents tested still allowed particle formation, however the HCV El produced in this way proved to be less stable, compared to the sulfonated material. This finally resulted in disulfide based aggregation of the HCV El.
- optimizations may include the addition of anti-oxidants and/or storing the material at a pH different than 7 to 8, which is in the art.
- the sulfonated material was used already for evaluation.
- Example 32 antigenic and immunogenic profile of sulfonated HCV El.
- Table 7 the reactivity with human sera of sulfonated HCV Els(his) 6 derived from Hansenula (CL leader, extracted with GuHCl, purified with Ni-IDA and finally formulated in 0.5% betain as a particle) was compared with alkylated HCV Els derived from mammalian cell culture. Although the overall (average) reactivity was identical, some major difference were noted for individual sera. This implies that the sulfonated material presents at least some of its epitopes in a different way compared to alkylated HCV El .
- HCV El with cysteines which are modified in a reversible way may be more immunogenic and thus have an increased potency as a vaccine protecting against HCV (chronic infection).
- HCV El with cysteines which are modified in a reversible way may be more immunogenic and thus have an increased potency as a vaccine protecting against HCV (chronic infection).
- the induction of a response to neo-epitopes induced by irrreversible blocking is less likely to occur.
- Example 33 specific removal of non-processed HCV El by heparin
- Heparin is known to bind to several viruses and consequently binding to the HCV envelope has already been suggested (Garson et al., 1999).
- heparin was biotinylated and interaction with HCV El analyzed in microtiterplates coated with either sulfonated HCV El from Hansenula, alkylated HCV El from Hansenula and alkylated HCV El from mammalian cell culture.
- alkylation is reducing this binding substantially, however, this may be caused by the specific alkylation agent (iodo-acetamide) used in this example.
- specific alkylation agent iodo-acetamide
- Example 34 identical reactivity of vaccinees with mammalian or yeast derived HCV El
- HCV E2 in Saccharomyces cerevisiae and Kluyveromyces lactis.
- the purified product was however, clearly different from the HCV E2 derived from mammalian cells (CHO), since a lower reactivity was observed with sera from chimpanzees immunized with mammalian derived HCV E2 while reactivity with monoclonal antibodies was higher for the yeast derived HCV E2.
- Such a difference in reactivity was not noted between the HCV El produced by mammalian cells or by yeast by the methods described here as shown in Figure 53.
- the reactivity of 7 different chimpanzee sera obtained after immunization with mammalian derived HCV El is identical for when tested with Hansenula or mammalian derived HCV El while the monoclonal antibody against HCV El shows also an almost equal reactivity.
- Two of the chimpanzees (Yoran and Marti) were involved in a prophylactic vaccine study and were able to clear an acute infection upon challenge while a control animal did not clear the infection.
- the other five chimpanzees (Ton, Phil, Marcel, Peggy, Femma) were involved in therapeutic vaccination studies and showed a reduction in liver damage, as measured by ALT in serum and/or histological activity index on liver biopsy, upon the HCV El immunizations.
- Immunoliposomes as enzyme-carriers (immunoenzyzomes) for antibody-directed enzyme prodrug therapy (ADEPT): optimization of prodrug activating capacity. Pharm.Res.,13,603-610 (1996).
- trimera mouse system a mouse model for hepatitis C infection and evaluation of therapeutic agents. June 6-9, 1999; Oral 4.3. In: 6th International Symposium on Hepatitis C & Related Viruses. Bethesda
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002444006A CA2444006A1 (en) | 2001-04-24 | 2002-04-24 | Expression of core-glycosylated hcv envelope proteins in yeast |
AU2002252856A AU2002252856A1 (en) | 2001-04-24 | 2002-04-24 | Expression of core-glycosylated hcv envelope proteins in yeast |
JP2002583615A JP4261195B2 (en) | 2001-04-24 | 2002-04-24 | Expression of yeast core-glycosylated HCV envelope proteins |
EP02721875A EP1414942A2 (en) | 2001-04-24 | 2002-04-24 | Expression of core-glycosylated hcv envelope proteins in yeast |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01870088.0 | 2001-04-24 | ||
EP01870088 | 2001-04-24 | ||
US30560401P | 2001-07-17 | 2001-07-17 | |
US60/305,604 | 2001-07-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002086100A2 true WO2002086100A2 (en) | 2002-10-31 |
WO2002086100A3 WO2002086100A3 (en) | 2004-02-19 |
Family
ID=34072546
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BE2002/000063 WO2002086100A2 (en) | 2001-04-24 | 2002-04-24 | Expression of core-glycosylated hcv envelope proteins in yeast |
PCT/BE2002/000062 WO2002085932A2 (en) | 2001-04-24 | 2002-04-24 | Constructs and methods for expression of recombinant hcv envelope proteins |
PCT/BE2002/000064 WO2002086101A2 (en) | 2001-04-24 | 2002-04-24 | Core-glycosylated hcv envelope proteins |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BE2002/000062 WO2002085932A2 (en) | 2001-04-24 | 2002-04-24 | Constructs and methods for expression of recombinant hcv envelope proteins |
PCT/BE2002/000064 WO2002086101A2 (en) | 2001-04-24 | 2002-04-24 | Core-glycosylated hcv envelope proteins |
Country Status (20)
Country | Link |
---|---|
US (3) | US7314925B2 (en) |
EP (3) | EP1414942A2 (en) |
JP (2) | JP4261195B2 (en) |
KR (1) | KR100950104B1 (en) |
CN (1) | CN1636050A (en) |
AR (3) | AR035867A1 (en) |
AU (3) | AU2002257392B2 (en) |
BR (2) | BR0209034A (en) |
CA (3) | CA2443740A1 (en) |
CZ (1) | CZ20032853A3 (en) |
HU (1) | HUP0303924A2 (en) |
MX (2) | MXPA03009632A (en) |
NZ (2) | NZ529019A (en) |
OA (1) | OA13092A (en) |
PL (1) | PL366621A1 (en) |
RU (1) | RU2274643C2 (en) |
SK (1) | SK13142003A3 (en) |
WO (3) | WO2002086100A2 (en) |
YU (1) | YU84103A (en) |
ZA (3) | ZA200308272B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004041853A2 (en) * | 2002-11-08 | 2004-05-21 | Innogenetics N.V. | Hcv vaccine compositions comprising e1 and ns3 peptides |
AU2011254055B2 (en) * | 2004-10-18 | 2012-12-20 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
US8728489B2 (en) | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
US8821892B2 (en) | 2004-10-18 | 2014-09-02 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040185061A1 (en) * | 1994-07-29 | 2004-09-23 | Innogenetics N.V. | Redox reversible HCV proteins with native-like conformation |
SK13142003A3 (en) * | 2001-04-24 | 2004-11-03 | Innogenetics Nv | Core-glycosylated HCV envelope proteins |
DE10143490C2 (en) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Recombinant MVA with the ability to express HCV structural antigens |
US7439042B2 (en) * | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
JP4371739B2 (en) * | 2003-09-02 | 2009-11-25 | 株式会社東芝 | Electronic device having serial ATA interface and power saving method of serial ATA bus |
EP1602664A1 (en) * | 2004-03-08 | 2005-12-07 | Innogenetics N.V. | HCV E1 comprising specific disulfide bridges |
EP1574517A1 (en) * | 2004-03-09 | 2005-09-14 | Innogenetics N.V. | HCV E1 comprising specific disulfide bridges |
JP4885476B2 (en) * | 2004-05-21 | 2012-02-29 | 株式会社日本触媒 | Method for introducing protein and / or peptide into cell |
US20060234360A1 (en) * | 2005-04-13 | 2006-10-19 | Paola Branduardi | Ascorbic acid production from D-glucose in yeast |
US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
US9216212B2 (en) * | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
PE20070796A1 (en) * | 2005-10-24 | 2007-08-15 | Wyeth Corp | PROTEIN PRODUCTION METHOD USING ANTI-SENESCENCE COMPOUNDS |
US8741633B2 (en) | 2006-05-19 | 2014-06-03 | Glycofi, Inc. | Recombinant vectors |
AU2015234338C1 (en) * | 2006-07-28 | 2017-07-20 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
AU2007288129B2 (en) * | 2006-08-25 | 2013-03-07 | The Macfarlane Burnet Institute For Medical Research And Public Health Limited | Recombinant HCV E2 glycoprotein |
US8580270B2 (en) | 2008-09-30 | 2013-11-12 | University Of Massachusetts | Respiratory synctial virus (RSV) sequences for protein expression and vaccines |
US20100104555A1 (en) * | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | HCV neutralizing epitopes |
DE102009044224A1 (en) * | 2009-10-09 | 2011-04-28 | PomBio Tech GmbH Starterzentrum der Universität des Saarlandes Campus Geb. A1-1 | Method for production of HCV virus-like particles |
US20130295167A1 (en) | 2010-12-22 | 2013-11-07 | Bayer Intellectual Property Gmbh | Enhanced immune response in bovine species |
US20140155469A1 (en) | 2011-04-19 | 2014-06-05 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors and viruses |
US9534039B2 (en) | 2011-05-09 | 2017-01-03 | Ablynx N.V. | Method for the production of immunoglobulin single variable domains |
BR112016019837A2 (en) * | 2014-02-28 | 2017-10-17 | Bayer Animal Health Gmbh | immunostimulatory plasmids |
RU2741347C2 (en) * | 2015-11-13 | 2021-01-25 | Тарлан МАММЕДОВ | Obtaining in vivo n-deglycosylated recombinant proteins by combined expression with endo h |
ES2740449T3 (en) * | 2015-12-22 | 2020-02-05 | Bisy E U | Yeast cell |
CA3037813A1 (en) | 2016-09-21 | 2018-03-29 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996004385A2 (en) * | 1994-07-29 | 1996-02-15 | Innogenetics N.V. | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
WO1999054735A1 (en) * | 1998-04-17 | 1999-10-28 | Innogenetics N.V. | Improved immunodiagnostic assays using reducing agents |
WO1999067285A1 (en) * | 1998-06-24 | 1999-12-29 | Innogenetics N.V. | Particles of hcv envelope proteins: use for vaccination |
WO2001030815A1 (en) * | 1999-10-27 | 2001-05-03 | Innogenetics N.V. | Redox reversible hcv proteins with native-like conformation |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4395395A (en) * | 1979-05-21 | 1983-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Detection of non-A, non-B hepatitis associated antigen |
EP0288198A3 (en) | 1987-04-20 | 1989-03-29 | Takeda Chemical Industries, Ltd. | Production of peptide |
US5135854A (en) | 1987-10-29 | 1992-08-04 | Zymogenetics, Inc. | Methods of regulating protein glycosylation |
US5698390A (en) * | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
US5683864A (en) * | 1987-11-18 | 1997-11-04 | Chiron Corporation | Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies |
US5350671A (en) * | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
JP2791418B2 (en) * | 1987-12-02 | 1998-08-27 | 株式会社ミドリ十字 | Method for producing heterologous protein, recombinant DNA, transformant |
NO177065C (en) * | 1988-09-26 | 1995-07-12 | Labofina Sa | Process for the preparation of enzymatically active human lysozyme |
US5747239A (en) * | 1990-02-16 | 1998-05-05 | United Biomedical, Inc. | Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines |
US6312889B1 (en) * | 1990-04-04 | 2001-11-06 | Chiron Corporation | Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies |
WO1992001800A1 (en) * | 1990-07-20 | 1992-02-06 | Chiron Corporation | Method for integrative transformation of yeast using dispersed repetitive elements |
CA2047792C (en) | 1990-07-26 | 2002-07-02 | Chang Y. Wang | Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines |
RU2148587C1 (en) | 1991-06-24 | 2000-05-10 | Чирон Корпорейшн | Polypeptide and method of its synthesis, reagent for immuno-analysis, method of assay of antibody presence, method of induction of immune response |
AU4659993A (en) | 1992-07-07 | 1994-01-31 | Merck & Co., Inc. | Vaccine comprising mixed pres1+pres2+s and core particle |
DE69432475T2 (en) * | 1993-11-04 | 2004-03-04 | Innogenetics N.V. | OF HUMAN T CELLS IMMUNODOMINANT EPIROPEN OF THE VIRUS DER C-HEPATITIS |
ZA9610456B (en) * | 1995-12-20 | 1997-06-20 | Novo Nordisk As | N-terminally extended proteins expressed in yeast |
US5935824A (en) * | 1996-01-31 | 1999-08-10 | Technologene, Inc. | Protein expression system |
DE69735242T2 (en) * | 1996-12-20 | 2006-09-21 | Novo Nordisk A/S | N-TERMINAL EXTENDED PROTEIN EXPRESSED IN YEAST |
JP2001522599A (en) * | 1997-11-06 | 2001-11-20 | イノジェネティックス・ナムローゼ・フェンノートシャップ | Multimeric peptide derived from hepatitis C virus envelope protein for diagnosis and vaccine |
EP1049790A1 (en) * | 1998-01-23 | 2000-11-08 | Novo Nordisk A/S | Process for making desired polypeptides in yeast |
WO2002055548A2 (en) | 2001-01-11 | 2002-07-18 | Innogenetics N.V. | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
SK13142003A3 (en) * | 2001-04-24 | 2004-11-03 | Innogenetics Nv | Core-glycosylated HCV envelope proteins |
IL162236A0 (en) | 2001-12-18 | 2005-11-20 | Innogenetics Nv | Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use |
WO2004041853A2 (en) * | 2002-11-08 | 2004-05-21 | Innogenetics N.V. | Hcv vaccine compositions comprising e1 and ns3 peptides |
-
2002
- 2002-04-24 SK SK1314-2003A patent/SK13142003A3/en unknown
- 2002-04-24 JP JP2002583615A patent/JP4261195B2/en not_active Expired - Fee Related
- 2002-04-24 CA CA002443740A patent/CA2443740A1/en not_active Abandoned
- 2002-04-24 OA OA1200500194A patent/OA13092A/en unknown
- 2002-04-24 US US10/128,587 patent/US7314925B2/en not_active Expired - Fee Related
- 2002-04-24 JP JP2002583616A patent/JP4173741B2/en not_active Expired - Fee Related
- 2002-04-24 BR BR0209034-1A patent/BR0209034A/en not_active IP Right Cessation
- 2002-04-24 US US10/128,590 patent/US7238356B2/en not_active Expired - Fee Related
- 2002-04-24 HU HU0303924A patent/HUP0303924A2/en unknown
- 2002-04-24 CZ CZ20032853A patent/CZ20032853A3/en unknown
- 2002-04-24 US US10/128,578 patent/US7048930B2/en not_active Expired - Fee Related
- 2002-04-24 NZ NZ529019A patent/NZ529019A/en unknown
- 2002-04-24 CN CNA028126076A patent/CN1636050A/en active Pending
- 2002-04-24 CA CA002444006A patent/CA2444006A1/en not_active Abandoned
- 2002-04-24 WO PCT/BE2002/000063 patent/WO2002086100A2/en active Application Filing
- 2002-04-24 YU YU84103A patent/YU84103A/en unknown
- 2002-04-24 AR ARP020101493A patent/AR035867A1/en unknown
- 2002-04-24 EP EP02721875A patent/EP1414942A2/en not_active Withdrawn
- 2002-04-24 EP EP02764023A patent/EP1381671A2/en not_active Withdrawn
- 2002-04-24 EP EP02727059A patent/EP1417298A2/en not_active Withdrawn
- 2002-04-24 MX MXPA03009632A patent/MXPA03009632A/en not_active Application Discontinuation
- 2002-04-24 AR ARP020101494A patent/AR035868A1/en unknown
- 2002-04-24 WO PCT/BE2002/000062 patent/WO2002085932A2/en active IP Right Grant
- 2002-04-24 AU AU2002257392A patent/AU2002257392B2/en not_active Ceased
- 2002-04-24 KR KR1020037013778A patent/KR100950104B1/en not_active IP Right Cessation
- 2002-04-24 BR BR0209033-3A patent/BR0209033A/en not_active IP Right Cessation
- 2002-04-24 AR ARP020101495A patent/AR035869A1/en unknown
- 2002-04-24 RU RU2003130955/13A patent/RU2274643C2/en not_active IP Right Cessation
- 2002-04-24 NZ NZ529324A patent/NZ529324A/en unknown
- 2002-04-24 AU AU2002308449A patent/AU2002308449B2/en not_active Ceased
- 2002-04-24 MX MXPA03009626A patent/MXPA03009626A/en not_active Application Discontinuation
- 2002-04-24 PL PL02366621A patent/PL366621A1/en not_active Application Discontinuation
- 2002-04-24 AU AU2002252856A patent/AU2002252856A1/en not_active Abandoned
- 2002-04-24 WO PCT/BE2002/000064 patent/WO2002086101A2/en active IP Right Grant
- 2002-04-24 CA CA002443781A patent/CA2443781A1/en not_active Abandoned
-
2003
- 2003-10-23 ZA ZA200308272A patent/ZA200308272B/en unknown
- 2003-10-23 ZA ZA200308277A patent/ZA200308277B/en unknown
- 2003-10-23 ZA ZA200308274A patent/ZA200308274B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996004385A2 (en) * | 1994-07-29 | 1996-02-15 | Innogenetics N.V. | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
WO1999054735A1 (en) * | 1998-04-17 | 1999-10-28 | Innogenetics N.V. | Improved immunodiagnostic assays using reducing agents |
WO1999067285A1 (en) * | 1998-06-24 | 1999-12-29 | Innogenetics N.V. | Particles of hcv envelope proteins: use for vaccination |
WO2001030815A1 (en) * | 1999-10-27 | 2001-05-03 | Innogenetics N.V. | Redox reversible hcv proteins with native-like conformation |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004041853A2 (en) * | 2002-11-08 | 2004-05-21 | Innogenetics N.V. | Hcv vaccine compositions comprising e1 and ns3 peptides |
WO2004041853A3 (en) * | 2002-11-08 | 2004-07-15 | Innogenetics Nv | Hcv vaccine compositions comprising e1 and ns3 peptides |
AU2011254055B2 (en) * | 2004-10-18 | 2012-12-20 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
US8821892B2 (en) | 2004-10-18 | 2014-09-02 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
US8728489B2 (en) | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7048930B2 (en) | Expression of core-glycosylated HCV envelope proteins in yeast | |
AU2002308449A1 (en) | Constructs and methods for expression of recombinant HCV envelope proteins | |
AU2002257392A1 (en) | Core-glycosylated hcv envelope proteins | |
EP1090033B2 (en) | Particles of hcv envelope proteins: use for vaccination | |
WO2003051912A9 (en) | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use | |
US20080124763A1 (en) | Constructs and methods for expression of recombinant proteins in methylotrophic yeast cells | |
US20050014136A1 (en) | Modified HCV NS5 | |
EP1224214A1 (en) | Redox reversible hcv proteins with native-like conformation | |
JP2004536582A (en) | Constructs and methods for expression of recombinant HCV envelope proteins | |
JP2007289204A (en) | Construct and method for expression of recombinant hcv envelop protein | |
SABLON et al. | Patent 2443740 Summary | |
BOSMAN et al. | Patent 2444006 Summary | |
HRP20030946A2 (en) | Core-glycosylated hcv envelope proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2444006 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/08272 Country of ref document: ZA Ref document number: 200308272 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002583615 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002721875 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2002721875 Country of ref document: EP |